<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Leukotriene receptor antagonists for eczema - Ferguson, L - 2018 | Cochrane Library</title> <meta content="Leukotriene receptor antagonists for eczema - Ferguson, L - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011224.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Leukotriene receptor antagonists for eczema - Ferguson, L - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011224.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011224.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Leukotriene receptor antagonists for eczema" name="citation_title"/> <meta content="Leila Ferguson" name="citation_author"/> <meta content="St Helier Hospital" name="citation_author_institution"/> <meta content="Masaki Futamura" name="citation_author"/> <meta content="Nagoya Medical Center" name="citation_author_institution"/> <meta content="masakifutamura@gmail.com" name="citation_author_email"/> <meta content="Efstratios Vakirlis" name="citation_author"/> <meta content="Aristotle University Medical School" name="citation_author_institution"/> <meta content="Reiji Kojima" name="citation_author"/> <meta content="School of Medicine, University of Yamanashi" name="citation_author_institution"/> <meta content="Hatoko Sasaki" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Amanda Roberts" name="citation_author"/> <meta content="Nottingham Support Group for Carers of Children with Eczema" name="citation_author_institution"/> <meta content="Rintaro Mori" name="citation_author"/> <meta content="National Center for Child Health and Development" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD011224.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/10/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011224.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011224.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011224.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Acetates [administration &amp; dosage, adverse effects, *therapeutic use]; Administration, Oral; Cyclopropanes; Eczema [*drug therapy]; Leukotriene Antagonists [administration &amp; dosage, adverse effects, *therapeutic use]; Quinolines [administration &amp; dosage, adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Sulfides" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011224.pub2&amp;doi=10.1002/14651858.CD011224.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="na56WA6j";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011224\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011224\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","pl","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011224.pub2",title:"Leukotriene receptor antagonists for eczema",firstPublishedDate:"Oct 21, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Skin Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011224.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011224.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011224.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011224.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011224.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011224.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011224.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011224.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011224.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011224.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>8944 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011224.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0116"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0070"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-sec-0108"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/appendices#CD011224-sec-0121"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/table_n/CD011224StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/table_n/CD011224StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Leukotriene receptor antagonists for eczema</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0002">Leila Ferguson</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Masaki Futamura</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0004">Efstratios Vakirlis</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0005">Reiji Kojima</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0006">Hatoko Sasaki</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0007">Amanda Roberts</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information#CD011224-cr-0008">Rintaro Mori</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information/en#CD011224-sec-0130">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 October 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011224.pub2">https://doi.org/10.1002/14651858.CD011224.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011224-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011224-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011224-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011224-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011224-abs-0001" lang="en"> <section id="CD011224-sec-0001"> <h3 class="title" id="CD011224-sec-0001">Background</h3> <p>Eczema is a common, chronic, inflammatory skin condition that is frequently associated with atopic conditions, including asthma. Leukotriene receptor antagonists (LTRAs) have a corticosteroid‐sparing role in asthma, but their role in eczema remains controversial. Currently available topical therapies for eczema are often poorly tolerated, and use of systemic agents is restricted by their adverse effect profile. A review of alternative treatments was therefore warranted. </p> </section> <section id="CD011224-sec-0002"> <h3 class="title" id="CD011224-sec-0002">Objectives</h3> <p>To assess the possible benefits and harms of leukotriene receptor antagonists for eczema. </p> </section> <section id="CD011224-sec-0003"> <h3 class="title" id="CD011224-sec-0003">Search methods</h3> <p>We searched the following databases to September 2017: the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, and the GREAT database. We also searched five trial registries, and handsearched the bibliographies of all extracted studies for further relevant trials. </p> </section> <section id="CD011224-sec-0004"> <h3 class="title" id="CD011224-sec-0004">Selection criteria</h3> <p>Randomised controlled trials of LTRAs alone or in combination with other (topical or systemic) treatments compared with other treatments alone such as topical corticosteroids or placebo for eczema in the acute or chronic (maintenance) phase of eczema in adults and children. </p> </section> <section id="CD011224-sec-0005"> <h3 class="title" id="CD011224-sec-0005">Data collection and analysis</h3> <p>We used the standard methodological procedures expected by Cochrane. The primary outcome measures were change in disease severity, long‐term symptom control, and adverse effects of treatment. Secondary outcomes were change in corticosteroid requirement, reduction of pruritis, quality of life, and emollient requirement. We used GRADE to assess the quality of the evidence for each outcome. </p> </section> <section id="CD011224-sec-0006"> <h3 class="title" id="CD011224-sec-0006">Main results</h3> <p>Only five studies (including a total of 202 participants) met the inclusion criteria, all of which assessed oral montelukast; hence, we found no studies assessing other LTRAs. Treatment ranged from four to eight weeks, and outcomes were assessed at the end of treatment; therefore, we could only report short‐term measurements (defined as less than three months follow‐up from baseline). Montelukast dosing was 10 mg for adults (age 14 years and above) and 5 mg for children (age 6 years to 14 years). One study included children (aged 6 years and above) among their participants, while the remaining studies only included adults (participant age ranged from 16 to 70 years). The participants were diagnosed with moderate‐to‐severe eczema in four studies and moderate eczema in one study. The study setting was unclear in two studies, multicentre in two studies, and single centre in one study; the studies were conducted in Europe and Bangladesh. Two studies were industry funded. The comparator was placebo in three studies and conventional treatment in two studies. The conventional treatment comparator was a combination of antihistamines and topical corticosteroids (plus oral antibiotics in one study). </p> <p>Four of the studies did not adequately describe their randomisation or allocation concealment method and were considered as at unclear risk of selection bias. Only one study was at low risk of performance and detection bias. However, we judged all studies to be at low risk of attrition and reporting bias. </p> <p>We found no evidence of a difference in disease severity of moderate‐to‐severe eczema after short‐term use of montelukast (10 mg) when compared with placebo. The outcome was assessed using the modified EASI (Eczema Area and Severity Index) score and SASSAD (Six Area, Six Sign Atopic Dermatitis) severity score (standardised mean difference 0.29, with a positive score showing montelukast is favoured, 95% confidence interval (CI) ‐0.23 to 0.81; 3 studies; n = 131; low‐quality evidence). </p> <p>When short‐term montelukast (10 mg) treatment was compared with conventional treatment in one study, the mean improvement in severity of moderate‐to‐severe eczema was greater in the intervention group (measured using SCORAD (SCORing of Atopic Dermatitis) severity index) (mean difference 10.57, 95% CI 4.58 to 16.56; n = 31); however, another study of 32 participants found no significant difference between groups using the same measure (mean improvement was 25.2 points with montelukast versus 23.9 points with conventional treatment; no further numerical data provided). We judged the quality of the evidence as very low for this outcome, meaning the results are uncertain. </p> <p>All studies reported their adverse event rate during treatment. Four studies (136 participants) reported no adverse events. In one study of 58 participants with moderate eczema who received montelukast 10 mg (compared with placebo), there was one case of septicaemia and one case of dizziness reported in the intervention group, both resulting in study withdrawal, although whether these effects were related to the medication is unclear. Mild side effects (e.g. headache and mild gastrointestinal disturbances) were also noted, but these were fairly evenly distributed between the montelukast and placebo groups. The quality of evidence for this outcome was low. </p> <p>No studies specifically evaluated emollient requirement or quality of life. One study that administered treatment for eight weeks specifically evaluated pruritus improvement at the end treatment and topical corticosteroid use during treatment. We found no evidence of a difference between montelukast (10 mg) and placebo for both outcomes (low‐quality evidence, n = 58). No other study assessed these outcomes. </p> </section> <section id="CD011224-sec-0007"> <h3 class="title" id="CD011224-sec-0007">Authors' conclusions</h3> <p>The findings of this review are limited to montelukast. There was a lack of evidence addressing the review question, and the quality of the available evidence for most of the measured outcomes was low. Some primary and secondary outcomes were not addressed at all, including long‐term control. </p> <p>We found no evidence of a difference between montelukast (10 mg) and placebo on disease severity, pruritus improvement, and topical corticosteroid use. Very low‐quality evidence means we are uncertain of the effect of montelukast (10 mg) compared with conventional treatment on disease severity. Participants in only one study reported adverse events, which were mainly mild (low‐quality evidence). </p> <p>There is no evidence that LTRA is an effective treatment for eczema. Serious limitations were that all studies focused on montelukast and only included people with moderate‐to‐severe eczema, who were mainly adults; and that each outcome was evaluated with a small sample size, if at all. </p> <p>Further large randomised controlled trials, with a longer treatment duration, of adults and children who have eczema of all severities may help to evaluate the effect of all types of LTRA, especially on eczema maintenance. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011224-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011224-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011224-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011224-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD011224-abs-0009">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011224-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011224-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011224-abs-0005" lang="en"> <h3>Are non‐steroidal anti‐inflammatory medicines known as leukotriene receptor antagonists helpful and safe for eczema? </h3> <p><b>Review question</b> </p> <p>We wanted to see if anti‐inflammatory leukotriene receptor antagonists (LTRAs) reduced symptoms or improved quality of life in adults and children with established eczema; if they are safe; and whether they could be recommended as an effective alternative eczema treatment. We included studies that compared LTRAs with other treatments alone, such as topical corticosteroids (anti‐inflammatory steroid (synthetic hormone) medications), or with placebo (an identical but inactive treatment). </p> <p><b>Background</b> </p> <p>Eczema, also called 'atopic eczema' and 'dermatitis', is a common dry skin condition. Eczema can be mild, moderate, or severe depending on how itchy or red the skin is, how much skin is affected, and its impact on daily life. Eczema is sometimes linked to a group of conditions, including asthma. Corticosteroids are a commonly used treatment, but long‐term treatment can produce unwanted side effects, such as skin thinning. LTRAs have been shown to improve asthma symptoms, and their use in eczema would reduce the amount of steroids used. LTRAs are not currently given for eczema, and whether they are effective for this condition is uncertain. </p> <p><b>Study characteristics</b> </p> <p>This evidence is current to September 2017. We found five studies with a total of 202 participants (both genders). All included participants had moderate‐to‐severe eczema diagnosed by a specialist doctor. The studies lasted four to eight weeks. The study setting was unclear in two studies, multicentre in two studies, and single centre in one study; the studies were conducted in Europe and Bangladesh. All studies used the LTRA montelukast, at a dose of either 5 mg or 10 mg. Only one study included children (31 participants, age 6 years and older). The age range for the other four studies was 16 to 70 years. LTRA treatment was compared with placebo or conventional treatment, which includes currently used eczema treatments, such as steroid creams. Varied scoring systems were used to calculate the effect of the treatments on participants' eczema. Two included studies were funded by the company that produces montelukast. </p> <p><b>Key results</b> </p> <p>Limited available data meant we were unable to draw firm conclusions on the effectiveness of LTRA in eczema. Like other reviews on this topic, this review is unlikely to change how eczema is treated because there is no convincing evidence that montelukast, the only LTRA that could be assessed, is helpful for eczema. </p> <p>We found no evidence of a difference between montelukast and placebo in terms of improving eczema disease severity (low‐quality evidence). When montelukast was compared with conventional treatment, participants using montelukast in one study saw an improvement in disease severity, but no difference was observed in another study. We are uncertain about these results because the quality of the evidence was very low. </p> <p>None of the studies looked at long‐term eczema control, moisturiser (emollients) use, or quality of life. </p> <p>We found no evidence that montelukast lessened itching or reduced the need for steroid creams during treatment when compared to placebo (low‐quality evidence). The studies comparing montelukast with conventional treatments did not assess these outcomes. </p> <p>Participants in four studies did not experience side effects. In one study comparing montelukast with placebo, there were two reported incidents in the montelukast group that resulted in participant withdrawal: one episode of septicaemia (blood poisoning) and one episode of dizziness. However, it was not clear whether these were related to the montelukast treatment. Other mild side effects were reported (e.g. headache, stomach‐related disturbances), but by participants in both groups. We therefore found no evidence of a difference between montelukast and placebo or conventional treatments, but this is assessment is based on low‐quality evidence. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence was low for all but one key result, that is montelukast’s effect on ‘change (improvement) in disease severity’ when compared with conventional treatment, the evidence for which was considered to be very low quality. Overall, very few studies addressed our review question. </p> <p>Many outcomes were not assessed, including long‐term control, and those that were assessed had relatively few participants, which were mainly adults. The studies focused solely on moderate‐severe eczema, and there were concerns with the participants or investigators knowing which treatment was received. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011224-sec-0116" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-sec-0116">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-sec-0187">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011224-sec-0116"></div> <h3 class="title" id="CD011224-sec-0117">Implications for practice</h3> <section id="CD011224-sec-0117"> <p>The overall objectives of this review were not well met by the evidence found: our findings are limited to montelukast, as this was the only leukotriene receptor antagonist (LTRA) used in all five studies. It is possible that the two studies assessing montelukast versus placebo in <a href="./references#CD011224-sec-0138" title="">Characteristics of studies awaiting classification</a> might have altered the conclusions of the review had more data been available from them. </p> <p>The majority of the participants in the included studies were adults, and all had either moderate or severe eczema. Furthermore, the trials were short term and did not measure some of our chosen outcomes. We were thus unable to draw conclusions on the effect of LTRA on children or those with mild or chronic eczema, as well as the following outcomes: need for emollient use, effect on long‐term control, or improvement in quality of life. </p> <p>We found no evidence of a difference between montelukast (10 mg) and placebo on disease severity, reduction of pruritus, or topical corticosteroid use (low‐quality evidence). </p> <p>Very‐low quality evidence means we are uncertain of the effect of montelukast (10 mg) compared with conventional treatment on disease severity. </p> <p>Participants in only one study reported adverse events, which were mainly mild (low‐quality evidence). </p> <p>Based on the evidence in this review, montelukast may add no benefit to current conventional eczema treatments more than placebo. </p> </section> <h3 class="title" id="CD011224-sec-0118">Implications for research</h3> <section id="CD011224-sec-0118"> <p>Given that the studies included in this review provided inconsistent results, we were unable to draw robust conclusions about the use of LTRA in eczema in the short term. Since most of the included studies focused on adults and lasted three months or less, further longer‐term research focusing on children may be worthwhile, as may further studies in adults. Future trials might include people with eczema of varying severity (including mild eczema). Encouragingly, a study awaiting classification that we identified is looking solely at the effect of LTRA in the paediatric population (<a href="./references#CD011224-bbs2-0021" title="MelamedIR , RobinsonL , HeffronM . The benefit of montelukast in atopic dermatitis induced by food allergies. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB93. [EMBASE: 70155473] ">Melamed 2010</a>). </p> <p>Future randomised controlled trials should be rigorously designed and conducted, including undertaking a sample size calculation and ensuring blinding. Furthermore, they should follow the CONSORT statement to ensure that they adequately report on methodological aspects as well as complete and transparent reporting (<a href="./references#CD011224-bbs2-0032" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332. [DOI: 10.1136/bmj.c332.] ">CONSORT 2010</a>). This will improve critical appraisal and interpretation as well as assessment of the validity of the results. </p> <p>Eczema should not be grouped together with other atopic conditions, such as asthma; otherwise, conclusions that are separate to the effects in asthma cannot be extracted. However, the subgroup of those with eczema and asthma would be worth evaluation, because this phenotype might represent a more responsive group than those with eczema only. One included study involved participants with both eczema and asthma (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>), but we could not conduct any sensitivity analyses. All the included studies used montelukast as the LTRA for intervention. The current evidence on adverse effects means that this continues to be the LTRA of choice, for the time being. Any future studies should specially report on adverse effects. </p> <p>Since the evidence does not currently support LTRA as an effective treatment for eczema, further studies comparing LTRA to placebo may be warranted. Longer‐term randomised controlled trials comparing montelukast with conventional treatment (topical steroids and emollients) versus conventional treatment alone that look at the effectiveness of LTRA as a maintenance therapy would only be worthwhile if positive effects were seen in trials of LTRA versus placebo. All studies included in this review had a treatment duration of eight weeks or less. A longer study period would enable evaluation of alternative outcome measures, such as flare‐free remission periods. Future studies might also assess other available LTRAs such as zafirlukast (sold as Accolate). </p> <p>Outcome measures currently in use include validated severity scores, and these are appropriate. Additional measures that would be beneficial include explicit recording of topical corticosteroid use to enable precise comparisons between groups, quality of life measures, emollient use, specific analysis of measures such as pruritus and sleep, as well as maintenance outcomes such as flare‐free periods. All measures reported should include measures of effect, such as standard deviation, to enable review authors to conduct meta‐analyses. </p> <p>Many cross‐over studies are being conducted in this area, due to the capacity of individuals to act as their own control. However, particularly with short study durations, this style of study is more challenging to analyse, as the effect of an intervention may hangover into the washout period and beyond. Additionally, eczema is a very variable condition, and this study design is more suited to constant chronic conditions rather than relapsing remitting types. Any future trials should report adequately on methods of allocation and potential sources of bias, as many studies analysed here did not. </p> <p>Conventional therapies in eczema involve laborious application of topical therapies and are often aimed at short‐term acute flare resolution. A longer‐term maintenance therapy that is more acceptable to patients is still needed. These recommendations for future research are valid to September 2017, the date of our last search. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011224-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011224-sec-0029"></div> <div class="table" id="CD011224-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Montelukast versus placebo for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Montelukast compared with placebo for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> eczema<br/> <b>Setting:</b> 2 studies were conducted in 2 centres each; setting of remaining study is unknown<br/> <b>Intervention:</b> montelukast<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Montelukast</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change (improvement) in disease severity</b> </p> <p>(4 to 8 weeks)</p> <p>SMD (modified EASI score and SASSAD)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement score ranged across placebo group from 0.68 to 1.9.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in the intervention group was 0.29 higher (0.23 lower to 0.81 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect of long‐term control</b> (&gt; 3 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured, as longest follow‐up was only 8 weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>(4 to 8 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 adverse events were reported (1 episode of septicaemia and 1 dizzy spell in the montelukast group) out of 29 participants (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> <p>No adverse effects were observed in the other 2 studies (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), but <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> reported an equivalent dropout rate in both montelukast and placebo groups due to aggravation of eczema or loss to follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Requirement for corticosteroid (steroid‐sparing</b> <br/> <b>effect)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The frequency of topical corticosteroids use was not significantly different between montelukast and placebo treatments using a 5‐point scale (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of pruritus</b> </p> <p>(score range 0 to 10; higher score means better improvement)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in improvement of pruritus score from baseline was 0.8 in the placebo group. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in improvement of pruritus score from baseline was 0.7 lower in the montelukast group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study authors assessed this difference as non‐significant (but no P value or standard deviations provided) (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies evaluated quality of life.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for emollient use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies evaluated emollient requirement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>EASI:</b> Eczema Area and Severity Index; <b>RCT:</b> randomised controlled trial; <b>SASSAD:</b> Six‐Area, Six‐Sign Atopic Dermatitis; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded by two levels, one level due to imprecision because the total number of participants included in all studies was insufficient; and one level due to indirectness because the studies only included adults with moderate‐to‐severe eczema, with no evidence from those with mild eczema or paediatric patients. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD011224-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Montelukast versus conventional treatment for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Montelukast compared with conventional treatment for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> eczema<br/> <b>Setting:</b> 1 study was conducted in a single centre; the setting of the other study is unknown<br/> <b>Intervention:</b> montelukast<br/> <b>Comparison:</b> conventional treatment (topical corticosteroid and oral antihistamine +/‐ oral antibiotics) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Conventional treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Montelukast</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change (improvement) in disease severity</b> </p> <p>(4 weeks)</p> <p>SCORAD score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in severity score was 4.73.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in severity score in the intervention group was 10.57 units greater (4.58 greater to 16.56 greater). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Another study with 32 participants reported no significant difference in SCORAD between the montelukast (mean improvement = 25.2 points) and conventional treatment (mean improvement = 23.9) (6 weeks follow‐up) groups (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>), but the authors did not provide the statistical values needed to calculate standard deviation, thus we could not pool these data. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect of long‐term control</b> (&gt; 3 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured, as longest follow‐up was only 6 weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>(4 to 6 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported no adverse effects (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Requirement for corticosteroid (steroid‐sparing</b> <br/> <b>effect)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of pruritus</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for emollient use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>SCORAD:</b> SCORing of Atopic Dermatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded by three levels: one level due to imprecision because the total number of participants included in the study was insufficient; a second level due to indirectness because the study only included adults with moderate‐to‐severe eczema, with no evidence from those with mild eczema or paediatric patients; and a third level due to risk of bias because the outcome assessors were not blinded.<br/> <sup>2</sup>We downgraded by two levels: one level due to imprecision because the total number of participants included in the studies was insufficient; and one level due to indirectness because the studies only included adults with moderate‐to‐severe eczema, with no evidence from those with mild eczema or paediatric patients. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011224-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-sec-0139">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD011224-sec-0030"></div> <section id="CD011224-sec-0031"> <h3 class="title" id="CD011224-sec-0031">Description of the condition</h3> <p>Eczema, also known as 'atopic eczema' or 'dermatitis', is a common, chronic, relapsing inflammatory skin condition (<a href="./references#CD011224-bbs2-0044" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy &amp; Clinical Immunology2004;113(5):832‐6. [PUBMED: 15131563] ">Johansson 2004</a>). Eczema causes dry itchy skin, which tends to flare intermittently, due to various internal and external factors (<a href="./references#CD011224-bbs2-0055" title="RingJ , AlomarA , BieberT , DeleuranM , Fink‐WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045‐60. [PUBMED: 22805051] ">Ring 2012</a>). </p> <p>Eczema often occurs in families with atopic diseases including asthma, allergic rhinitis/hay fever (and food allergy), and atopic eczema. These diseases share a common pathogenesis, and are frequently present together in the same individual and family. The word 'atopy' refers to the genetic tendency to produce immunoglobulin E (IgE) antibodies in response to small amounts of common environmental proteins such as pollen, house dust mite, and food allergens (<a href="./references#CD011224-bbs2-0064" title="StoneKD . Atopic diseases of childhood. Current Opinion in Pediatrics2002;14(5):634‐46. [PUBMED: 12352260] ">Stone 2002</a>; <a href="./references#CD011224-bbs2-0066" title="ThomsenSF . Epidemiology and natural history of atopic diseases. European Clinical Respiratory Journal2015;2(1):24642. [PUBMED: 26557262] ">Thomsen 2015</a>). Around 30% of people with eczema develop asthma, and 35% develop allergic rhinitis (<a href="./references#CD011224-bbs2-0048" title="LuomaR , KoivikkoA , VianderM . Development of asthma, allergic rhinitis and atopic dermatitis by the age of five years. A prospective study of 543 newborns. Allergy1983;38(5):339–46. [PUBMED: 6614406] ">Luoma 1983</a>). However, it is known that atopy does not concurrently occur in all people with atopic eczema. In view of this, there have been proposals to use the term 'eczema' to define people both with and without atopy. In agreement with the 'revised nomenclature for allergy for global use' (<a href="./references#CD011224-bbs2-0044" title="JohanssonSG , BieberT , DahlR , FriedmannPS , LanierBQ , LockeyRF , et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. Journal of Allergy &amp; Clinical Immunology2004;113(5):832‐6. [PUBMED: 15131563] ">Johansson 2004</a>), and similar to other Cochrane Reviews evaluating eczema therapies (<a href="./references#CD011224-bbs2-0067" title="vanZuurenEJ , FedorowiczZ , ChristensenR , LavrijsenA , ArentsBWM . Emollients and moisturisers for eczema. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD012119.pub2] ">van Zuuren 2017</a>), we have therefore used the term 'eczema' throughout the review. </p> <p>Eczema presents early in life in most cases. Around 65% of children with eczema are affected by 18 months of age. Some of these cases resolve in early childhood, and by adulthood, 60% have resolved (<a href="./references#CD011224-bbs2-0063" title="SpergelJM . Epidemiology of atopic dermatitis and atopic march in children. Immunology &amp; Allergy Clinics of North America2010;30(3):269‐80. [PUBMED: 20670812] ">Spergel 2010</a>). Although the prevalence is lower in adults, for those who have the condition, it is often more severe and chronic in nature (<a href="./references#CD011224-bbs2-0047" title="KatsarouA , ArmenakaM . Atopic dermatitis in older patients: particular points. Journal of the European Academy of Dermatology and Venereology2011;25(1):12‐8. [PUBMED: 20569298] ">Katsarou 2011</a>). The most distressing symptom is itching, which causes skin damage and in turn more itching (i.e. the itch‐scratch cycle), which leads to the visible signs of eczema (<a href="./references#CD011224-bbs2-0070" title="YarbroughKB , NeuhausKJ , SimpsonEL . The effects of treatment on itch in atopic dermatitis. Dermatologic Therapy2013;26(2):110‐9. [PUBMED: 23551368] ">Yarbrough 2013</a>). The impact on quality of life can be considerable, especially in severe cases. Eczema can reduce school or work attendance (<a href="./references#CD011224-bbs2-0042" title="HolmEA , EsmannS , JemecGB . The handicap caused by atopic dermatitis‐‐sick leave and job avoidance. Journal of the European Academy of Dermatology and Venereology2006;20(3):255‐9. [PUBMED: 16503882] ">Holm 2006</a>), and can lead to disturbed sleep for the affected person and their family (<a href="./references#CD011224-bbs2-0049" title="MooreK , DavidTJ , MurrayCS , ChildF , ArkwrightPD . Effect of childhood eczema and asthma on parental sleep and well‐being: a prospective comparative study. British Journal of Dermatology2006;154(3):514‐8. [PUBMED: 16445784] ">Moore 2006</a>; <a href="./references#CD011224-bbs2-0054" title="ReidP , Lewis‐JonesMS . Sleep difficulties and their management in preschoolers with atopic eczema. Clinical and Experimental Dermatology1995;20(1):38‐41. [PUBMED: 7671394] ">Reid 1995</a>). </p> <p>Eczema is a multifactorial disease, with genetic and environmental factors contributing to varying extents in different individuals and populations (<a href="./references#CD011224-bbs2-0065" title="ThomsenSF , UlrikCS , KyvikKO , HjelmborgJv , SkadhaugeLR , SteffensenI , et al. Importance of genetic factors in the etiology of atopic dermatitis: a twin study. Allergy and Asthma Proceedings2007;28(5):535‐9. [PUBMED: 18034971] ">Thomsen 2007</a>). It is a chronic condition, so effective management involves recognising triggers, reducing allergens and irritants, and frequent emollient application (<a href="./references#CD011224-bbs2-0023" title="AkdisCA , AkdisM , BieberT , Bindslev‐JensenC , BoguniewiczM , EigenmannP , et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report. Journal of Allergy and Clinical Immunology2006;118(1):152‐69. [PUBMED: 16815151] ">Akdis 2006</a>). In addition, topical corticosteroids and calcineurin inhibitors are sometimes required (<a href="./references#CD011224-bbs2-0035" title="EichenfieldLF , TomWL , BergerTG , KrolA , PallerAS , SchwarzenbergerK , et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. Journal of the American Academy of Dermatology2014;71(1):116‐32. [PUBMED: 24813302] ">Eichenfield 2014</a>). </p> <p>Global prevalence studies suggest that eczema is widespread throughout the world, in low‐, middle‐, and high‐income countries, and recent research shows that eczema prevalence is rising (<a href="./references#CD011224-bbs2-0051" title="OdhiamboJA , WilliamsHC , ClaytonTO , RobertsonCF , AsherMI , ISAAC Phase Three Study Group. Global variations in prevalence of eczema symptoms in children from ISAAC Phase Three. Journal of Allergy &amp; Clinical Immunology2009;124(6):1251‐8. [PUBMED: 20004783] ">Odhiambo 2009</a>). Eczema affects daily activities and quality of life as well as consuming a significant portion of time and funding in both primary and secondary care (<a href="./references#CD011224-bbs2-0038" title="GuptaR , SheikhA , StrachanDP , AndersonHR . Burden of allergic disease in the UK: secondary analyses of national databases. Clinical &amp; Experimental Allergy2004;34(4):520‐6. [PUBMED: 15080802] ">Gupta 2004</a>). Parents of children who suffer from eczema, adults with eczema, and clinicians alike would welcome other topical therapies for the management of eczema during both the maintenance and exacerbation phases. Given the concern about local side effects with topical corticosteroid use, there is a particularly strong drive to find other treatments to treat exacerbations of eczema (<a href="./references#CD011224-bbs2-0039" title="Guttman‐YasskyE , DhingraN , LeungDY . New era of biologic therapeutics in atopic dermatitis. Expert Opinion on Biological Therapy2013;13(4):549‐61. [PUBMED: 23323893] ">Guttman‐Yassky 2013</a>). </p> </section> <section id="CD011224-sec-0032"> <h3 class="title" id="CD011224-sec-0032">Description of the intervention</h3> <p>During an exacerbation of eczema, the mainstay of treatment is the daily application of topical corticosteroids of varied strength depending on the severity of the flare and the site of involvement (<a href="./references#CD011224-bbs2-0036" title="EichenfieldLF , TomWL , ChamlinSL , FeldmanSR , HanifinJM , SimpsonEL , et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology2014;70(2):338‐51. [PUBMED: 24290431] ">Eichenfield 2014a</a>; <a href="./references#CD011224-bbs2-0055" title="RingJ , AlomarA , BieberT , DeleuranM , Fink‐WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045‐60. [PUBMED: 22805051] ">Ring 2012</a>). Due to unwanted side effects such as skin thinning, clinicians usually prescribe topical corticosteroids at the lowest effective potency for short durations, typically no more than 14 days (<a href="./references#CD011224-bbs2-0050" title="National Institute for Health and Clinical Excellence. Atopic eczema in children. Management of atopic eczema in children from birth up to the age of 12 years. NICE clinical guideline 572007. [www.nice.org.uk/nicemedia/pdf/cg057niceguideline.pdf] ">NICE 2007</a>). If topical corticosteroids alone are ineffective, clinicians sometimes have no alternative but to ascend the treatment ladder to oral corticosteroids during periods of severe flares (<a href="./references#CD011224-bbs2-0056" title="RingJ , AlomarA , BieberT , DeleuranM , Fink‐WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) Part II. Journal of the European Academy of Dermatology and Venereology2012;26(9):1176‐93. [PUBMED: 22813359] ">Ring 2012a</a>). </p> <p>Other topical treatments apart from corticosteroids exist, such as topical calcineurin inhibitors, pimecrolimus, and tacrolimus, but none have been found to be superior, and each treatment has its own side effect profile that restricts its use (<a href="./references#CD011224-bbs2-0026" title="AshcroftDM , ChenLC , GarsideR , SteinK , WilliamsHC . Topical pimecrolimus for eczema. Cochrane Database of Systematic Reviews2007, Issue 4. [DOI: 10.1002/14651858.CD005500.pub2; PUBMED: 17943859] ">Ashcroft 2007</a>). Eczema sufferers and carers of children with eczema attempt to comply with complex schedules of topical treatment and emollient application, but often find these difficult to adhere to when combined with everyday demands (<a href="./references#CD011224-bbs2-0028" title="BassAM , AndersonKL , FeldmanSR . Interventions to increase treatment adherence in pediatric atopic dermatitis: a systematic review. Journal of Clinical Medicine2015;4(2):231‐42. [PUBMED: 26239125] ">Bass 2015</a>). </p> <p>People with severe eczema who do not respond to topical therapy require systemic therapies, such as corticosteroids, antihistamines, antibiotics, ciclosporin, azathioprine, mycophenolate mofetil, methotrexate, and leflunomide; biologics; and phototherapy (<a href="./references#CD011224-bbs2-0062" title="SimonD . Systemic therapy of atopic dermatitis in children and adults. Current Problems in Dermatology2011;41:156‐64. [MEDLINE: 21576956] ">Simon 2011</a>). </p> <p>Topical corticosteroids are the first‐line treatment for eczema exacerbations (<a href="./references#CD011224-bbs2-0036" title="EichenfieldLF , TomWL , ChamlinSL , FeldmanSR , HanifinJM , SimpsonEL , et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology2014;70(2):338‐51. [PUBMED: 24290431] ">Eichenfield 2014a</a>; <a href="./references#CD011224-bbs2-0055" title="RingJ , AlomarA , BieberT , DeleuranM , Fink‐WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045‐60. [PUBMED: 22805051] ">Ring 2012</a>). However, patients, their families, and healthcare professionals try to limit their use because of their potential unwanted side effects or the widespread fear of corticosteroids (corticophobia) (<a href="./references#CD011224-bbs2-0025" title="ArtikS , RuzickaT . Complementary therapy for atopic eczema and other allergic skin diseases. Dermatologic Therapy2003;16(2):150‐63. [PUBMED: 12919117] ">Artik 2003</a>). In many cases, concerns about the potential for side effects often result in underuse of topical corticosteroids, leaving the eczema poorly controlled (<a href="./references#CD011224-bbs2-0024" title="ArkwrightPD , MotalaC , SubramanianH , SpergelJ , SchneiderLC , WollenbergA . Management of difficult‐to‐treat atopic dermatitis. Journal of Allergy and Clinical Immunology. In practice2013;1(2):142‐51. [PUBMED: 24565453] ">Arkwright 2013</a>). Topical corticosteroids are categorised by strength: mild, moderate, potent, or very potent (<a href="./references#CD011224-bbs2-0055" title="RingJ , AlomarA , BieberT , DeleuranM , Fink‐WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045‐60. [PUBMED: 22805051] ">Ring 2012</a>). The main side effect of skin thinning is typically observed after application of very potent preparations, especially in sensitive skin areas (e.g. facial or genital eczema), for prolonged periods, as is sometimes necessary in cases of severe eczema (<a href="./references#CD011224-bbs2-0030" title="CallenJ , ChamlinS , EichenfieldLF , EllisC , GirardiM , GoldfarbM , et al. A systematic review of the safety of topical therapies for atopic dermatitis. British Journal of Dermatology2007;156(2):203‐21. [PUBMED: 17223859] ">Callen 2007</a>). Systemic corticosteroids can be used for the treatment of severe cases of eczema and are often prescribed for a short course, since long‐term use can have numerous side effects, including metabolic, central nervous system, musculoskeletal, cutaneous, and ophthalmic disorders, and suppression of the immune system (<a href="./references#CD011224-bbs2-0061" title="SidburyR , DavisDM , CohenDE , CordoroKM , BergerTG , BergmanJN , et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology2014;71(2):327‐49. [PUBMED: 24813298] ">Sidbury 2014</a>). Systemic administration of steroids improves the clinical appearance of the lesions and relieves symptoms, but the disease quickly relapses once the medication is discontinued (<a href="./references#CD011224-bbs2-0061" title="SidburyR , DavisDM , CohenDE , CordoroKM , BergerTG , BergmanJN , et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology2014;71(2):327‐49. [PUBMED: 24813298] ">Sidbury 2014</a>). Other treatments without such side effects would therefore be welcomed. </p> <p>Leukotrienes are a class of inflammatory mediators derived from arachidonic acid through the 5‐lipoxygenase pathway (<a href="./references#CD011224-bbs2-0043" title="IversenL , KristensenP , GronB , ZibohVA , KragballeK . Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. Archives of Dermatological Research1994;286(5):261‐6. [PUBMED: 7914721] ">Iversen 1994</a>). The use of leukotriene receptor antagonists (LTRAs) as an anti‐inflammatory medicine in successfully treating asthma has been widely confirmed in the literature (<a href="./references#CD011224-bbs2-0029" title="BisgaardH , ZielenS , Garcia‐GarciaML , JohnstonSL , GillesL , MentenJ , et al. Montelukast reduces asthma exacerbations in 2‐ to 5‐year‐old children with intermittent asthma. American Journal of Respiratory &amp; Critical Care Medicine2005;171(4):315‐22. [PUBMED: 15542792] ">Bisgaard 2005</a>; <a href="./references#CD011224-bbs2-0057" title="RobertsonCF , PriceD , HenryR , MellisC , GlasgowN , FitzgeraldD , et al. Short‐course montelukast for intermittent asthma in children: a randomized controlled trial. American Journal of Respiratory &amp; Critical Care Medicine2007;175(4):323‐9. [PUBMED: 17110643] ">Robertson 2007</a>). The two most widely prescribed LTRAs are montelukast (sold as Singulair) and zafirlukast (sold as Accolate) (<a href="./references#CD011224-bbs2-0027" title="AsthmaCanada . Leukotriene receptor antagonists (LTRAs). www.asthma.ca/get‐help/asthma‐3/treatment/leukotriene/ (accessed 29 August 2018). ">Asthma Canada 2018</a>). The US Food and Drug Administration and public health organisations in other countries have approved the prescription of the LTRA montelukast for long‐term preventive therapy for young children with asthma (<a href="./references#CD011224-bbs2-0053" title="PapadopoulosNG , ArakawaH , CarlsenKH , CustovicA , GernJ , LemanskeR , et al. International consensus on (ICON) pediatric asthma. Allergy2012;67(8):976‐97. [PUBMED: 22702533] ">Papadopoulos 2012</a>). Normally prescribed in oral form, LTRAs are currently thought to be safe to use for both adults and children (<a href="./references#CD011224-bbs2-0031" title="ChauhanBF , DucharmeFM . Anti‐leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD002314.pub3] ">Chauhan 2012</a>). The global asthmatic guidelines recommend LTRAs for children aged five years and younger (<a href="./references#CD011224-bbs2-0037" title="Global Initiative forAsthma . Global Strategy for Asthma Management and Prevention. www.ginasthma.org/local/uploads/files/GINA_Report_2014_Jun11.pdf​ (accessed 15 July 2014). ">GINA 2014</a>). Although LTRAs are not superior to corticosteroids as monotherapy for asthma (<a href="./references#CD011224-bbs2-0031" title="ChauhanBF , DucharmeFM . Anti‐leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD002314.pub3] ">Chauhan 2012</a>), they have a role as a corticosteroid‐sparing agent in chronic asthma (<a href="./references#CD011224-bbs2-0045" title="JoosS , MikschA , SzecsenyiJ , WieselerB , GrouvenU , KaiserT , et al. Montelukast as add‐on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax2008;63(5):453‐62. [PUBMED: 18443162] ">Joos 2008</a>). In terms of acute asthma, there is no supporting evidence to use oral LTRAs in adults and children (<a href="./references#CD011224-bbs2-0068" title="WattsK , ChavasseRJ . Leukotriene receptor antagonists in addition to usual care for acute asthma in adults and children. Cochrane Database of Systematic Reviews2012, Issue 5. [DOI: 10.1002/14651858.CD006100.pub2; PUBMED: 22592708] ">Watts 2012</a>). Topical corticosteroids are pivotal in the treatment of eczema, in the way that inhaled corticosteroids are for asthma (<a href="./references#CD011224-bbs2-0033" title="DarsowU , LubbeJ , TaiebA , SeidenariS , WollenbergA , CalzaAM , et al. Position paper on diagnosis and treatment of atopic dermatitis. Journal of the European Academy of Dermatology and Venereology2005;19(3):286‐95. [PUBMED: 15857453] ">Darsow 2005</a>). To our knowledge, LTRAs are not routinely prescribed for eczema. However, it is possible that LTRAs may have a role in the treatment of eczema as they have in asthma, particularly given their potential as a steroid‐sparing agent. </p> <p>Given their role in long‐term prevention in asthma as well as their safety profile in asthma studies, it is possible that LTRAs may have a similar role in eczema. Many people with eczema find currently available topical treatments to be time‐consuming to apply and inconvenient. Alternative oral agents available to people with eczema are either restricted to short‐term use (prednisolone) or have significant safety concerns (e.g. ciclosporin, methotrexate, and other systemic agents). Leukotriene receptor antagonists, which can be administered orally and purport an acceptable safety profile, were therefore worth reviewing. The available research to date has shown conflicting results, and there exists some controversy as to the efficacy of LTRA in eczema. We decided to conduct this review to address this uncertainty. </p> </section> <section id="CD011224-sec-0033"> <h3 class="title" id="CD011224-sec-0033">How the intervention might work</h3> <p>One study, <a href="./references#CD011224-bbs2-0022" title="Adamek‐GuzikT , GuzikTJ , Czerniawska‐MysikG , KorpantyG , MastalerzL , RadwanJ , et al. Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status. Allergy2002;57(8):732‐6. [PUBMED: 12121194] ">Adamek‐Guzik 2002</a>, noted that the level of urinary leukotriene increased during exacerbations of eczema in adults, and that there was no difference in levels of urinary leukotriene between non‐eczematous healthy controls and eczema participants during remission phases. It would therefore be reasonable to suppose that leukotriene production may correlate with skin inflammation during flares of eczema. Additionally, one study, <a href="./references#CD011224-bbs2-0052" title="OymarK , AksnesL . Increased levels of urinary leukotriene E4 in children with severe atopic eczema/dermatitis syndrome. Allergy2005;60(1):86‐9. [PUBMED: 15575936] ">Oymar 2005</a>, observed increased urinary leukotriene E4 in children with severe eczema. This suggests there may in fact be a relationship between the degree or severity of skin inflammation and leukotriene production. This evidence prompted the idea that the blockade of leukotriene production with LTRAs may help reduce skin inflammation, and therefore LTRAs may be effective in treating eczema. Leukotriene receptor antagonists might have a corticosteroid‐sparing effect that would be beneficial in eczema (<a href="./references#CD011224-bbs2-0060" title="SherLG , ChangJ , PatelIB , BalkrishnanR , FleischerABJr . Relieving the pruritus of atopic dermatitis: a meta‐analysis. Acta Dermato‐Venereologica2012;92(5):455‐61. [PUBMED: 22773026] ">Sher 2012</a>). </p> </section> <section id="CD011224-sec-0034"> <h3 class="title" id="CD011224-sec-0034">Why it is important to do this review</h3> <p>Eczema is a common worldwide skin disease treated by primary care physicians, dermatologists, and paediatricians. Patients and caregivers often have a strong desire to find alternatives to corticosteroids. If shown to be effective and safe, LTRAs are candidates for inclusion in eczema treatment procedures because they might reduce the use of topical corticosteroids. Previous studies of LTRAs for eczema have shown conflicting results. This systematic review aimed to provide evidence about the effectiveness of LTRAs in eczema and to review the safety profile of LTRAs in people with eczema. </p> <p>The plans for this review were published as a protocol 'Leukotriene receptor antagonists for atopic eczema' (<a href="./references#CD011224-bbs2-0071" title="FutamuraM , FergusonL , VakirlisE , KojimaR , RobertsA , MoriR . Leukotriene receptor antagonists for atopic eczema. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD011224] ">Futamura 2014</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011224-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-sec-0144">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011224-sec-0035"></div> <p>To assess the possible benefits and harms of leukotriene receptor antagonists for eczema. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011224-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-sec-0145">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011224-sec-0036"></div> <section id="CD011224-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011224-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included all randomised controlled trials, both published and unpublished. We included trials reported only as abstracts if sufficient information was available to assess methodology and risk of bias. </p> <p>We did not include cross‐over trials or quasi‐randomised trials.</p> </section> <section id="CD011224-sec-0039"> <h4 class="title">Types of participants</h4> <p>We included adults and children with established eczema. A physician's diagnosis of eczema was compulsory. We included all trial settings, and we did not restrict for inclusion by age, ethnicity, or gender of participants, or severity of eczema. </p> </section> <section id="CD011224-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Interventions included treatment with systemic (oral or intravenous) LTRAs alone or in combination with other (topical or systemic) treatments in the acute or chronic (maintenance) phase of eczema compared with other treatments alone or placebo. Other treatments included all topical or systemic treatment, including corticosteroids, topical calcineurin inhibitors, immunomodulators, and alternative medicines. </p> <p>We excluded trials comparing other interventions with the same dose of LTRA between groups, that is a trial assessing groups with LTRA and treatment A versus LTRA and treatment B. These trials do not test the effects of LTRAs, but instead the efficacy of other treatments. </p> </section> <section id="CD011224-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>We reviewed the primary and secondary outcomes listed below. We divided results into effects in the short term, which we defined as less than three months, and long term, which we defined as three months or more. </p> <section id="CD011224-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD011224-list-0001"> <li> <p>Change in disease severity assessed by SCORAD (SCORing of Atopic Dermatitis) severity index, EASI (Eczema Area and Severity Index), SASSAD (Six Area, Six Sign Atopic Dermatitis) severity score, IGA (Investigator's Global Assessment), or any validated scoring system for eczema in the short and long term. A reduction in the score using these validated scoring systems equates to an improvement of the participant's eczema. </p> </li> <li> <p>Effect of long‐term control, such as time to relapse of 'flare' in the maintenance (flare‐free) phase. </p> </li> <li> <p>All adverse events, including allergic reactions and impact on quality of life and skin. </p> </li> </ol> </p> </section> <section id="CD011224-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD011224-list-0002"> <li> <p>Requirement for any topical or systemic corticosteroids, i.e. LTRA permits the lowering or minimising of the dose of corticosteroids needed, thus sparing some of the undesirable side effects of corticosteroids. </p> </li> <li> <p>Reduction of pruritus.</p> </li> <li> <p>Improvement in quality of life with any validated scoring system.</p> </li> <li> <p>Need for emollient use.</p> </li> </ol> </p> <section id="CD011224-sec-0044"> <h6 class="title">'Summary of findings' table</h6> <p>We included two 'Summary of findings' tables in which we summarised the findings for both our primary and secondary outcomes for the most important comparisons. We used the GRADE definitions to assess the quality of the evidence in the included studies for each outcome, which we summarised in the 'Summary of findings' tables. The GRADE assessments were based on five domains: study limitations (risk of bias), inconsistency of results, indirectness of evidence, imprecision, and publication bias. Evidence could be downgraded for these domains from high to moderate, low, or very low (<a href="./references#CD011224-bbs2-0059" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editors. GRADE handbook for grading quality of evidence and strength of recommendations. gdt.gradepro.org/app/handbook/handbook.html (accessed prior to 29 August 2018). ">Schünemann 2013</a>). </p> </section> </section> </section> </section> <section id="CD011224-sec-0045"> <h3 class="title">Search methods for identification of studies</h3> <p>We aimed to identify all relevant randomised controlled trials regardless of language or publication status (published, unpublished, in press, or in progress). </p> <section id="CD011224-sec-0046"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Skin Information Specialist searched the following databases up to 7 September 2017 using strategies based on the draft strategy for MEDLINE in our published protocol (<a href="./references#CD011224-bbs2-0071" title="FutamuraM , FergusonL , VakirlisE , KojimaR , RobertsA , MoriR . Leukotriene receptor antagonists for atopic eczema. Cochrane Database of Systematic Reviews2014, Issue 7. [DOI: 10.1002/14651858.CD011224] ">Futamura 2014</a>): </p> <p> <ul id="CD011224-list-0003"> <li> <p>the Cochrane Skin Specialised Register using the strategy in <a href="./appendices#CD011224-sec-0122">Appendix 1</a>; </p> </li> <li> <p>the Cochrane Central Register of Controlled Trials (CENTRAL) (2017, Issue 8), in the Cochrane Library using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-02" target="_blank">Appendix 2</a>; </p> </li> <li> <p>MEDLINE via Ovid (from 1946) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-03" target="_blank">Appendix 3</a>; </p> </li> <li> <p>Embase via Ovid (from 1974) using the strategy in <a href="http://archie.cochrane.org/sections/documents/view?document=205602041915453638%26format=REVMAN#APP-04" target="_blank">Appendix 4</a>; and </p> </li> <li> <p>the Global Resource for EczemA Trials (GREAT) (Centre of Evidence Based Dermatology (<a href="http://www.greatdatabase.org.uk" target="_blank">www.greatdatabase.org.uk</a>)) using the strategy in <a href="./appendices#CD011224-sec-0126">Appendix 5</a>. </p> </li> </ul> </p> <p>We (the review author team) searched the following database up to 7 September 2017:</p> <p> <ul id="CD011224-list-0004"> <li> <p>ISI Web of Science (from 1945) using the strategy in <a href="./appendices#CD011224-sec-0127">Appendix 6</a>. </p> </li> </ul> </p> <section id="CD011224-sec-0047"> <h5 class="title">Trial registries</h5> <p>We (the review author team) searched the following trial registries to 7 September 2017 using the terms 'atopic eczema (dermatitis)', 'leukotriene', 'montelukast', 'zafirlukast', 'zileuton', and 'pranlukast': </p> <p> <ul id="CD011224-list-0005"> <li> <p>the ISRCTN registry (<a href="http://www.isrctn.com" target="_blank">www.isrctn.com</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>the Australian New Zealand Clinical Trials Registry (<a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/trialsearch" target="_blank">www.who.int/trialsearch</a>); and </p> </li> <li> <p>the EU Clinical Trials Register (<a href="http://www.clinicaltrialsregister.eu/" target="_blank">www.clinicaltrialsregister.eu/</a>). </p> </li> </ul> </p> </section> </section> <section id="CD011224-sec-0048"> <h4 class="title">Searching other resources</h4> <section id="CD011224-sec-0049"> <h5 class="title">References from included studies</h5> <p>We checked the bibliographies of the included studies for further references to relevant trials. </p> </section> <section id="CD011224-sec-0050"> <h5 class="title">Adverse effects</h5> <p>Although we did not perform an adverse events search, we assessed all effects of LTRA reported in the treatment trials identified by our search, including any reported adverse effects or events. We acknowledge that these studies were not specifically designed to identify adverse effects, but we felt it would be useful to include these data as it is highly relevant to clinical decision‐making. </p> </section> </section> </section> <section id="CD011224-sec-0051"> <h3 class="title" id="CD011224-sec-0051">Data collection and analysis</h3> <p>Some parts of the Methods section of this review use text that was originally published in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011224-bbs2-0041" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), or have been taken from a standard template used by the Cochrane Pregnancy and Childbirth Review Group. </p> <section id="CD011224-sec-0052"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MF and LF) independently selected the trials according to the inclusion criteria. Any differences of opinion were resolved through discussion by consulting a third review author (RM) if required. </p> </section> <section id="CD011224-sec-0053"> <h4 class="title">Data extraction and management</h4> <p>We designed a data extraction form. Two review authors (MF and LF) independently extracted the data from eligible studies using the agreed‐upon form. We sought to record the study design, characteristics of participants, and types of interventions and doses of treatment used in each study. We also recorded the demographics of participants, results according to our outcome measures, and adverse effects. We further recorded methods of randomisation, treatment concealment, etc. to enable a 'Risk of bias' assessment for each study. Any discrepancies were resolved through discussion or by consulting a third review author (RM) if required. We entered data into Review Manager 5 and checked the data entry for accuracy. When any information was unclear, we attempted to contact the authors of the original reports to ask them to provide further details. Data expressed in figures without actual numbers were extracted using WebPlotDigitizer software (<a href="./references#CD011224-bbs2-0069" title="AnkitRohatgi . WebPlotDigitizer. Version 3.12. Austin, Texas, USA, 2017. ">WebPlotDigitizer</a>). </p> </section> <section id="CD011224-sec-0054"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (MF and RK) independently assessed the risk of bias for eligible studies, which we summarised in the 'Risk of bias' table for each included study in <a href="./references#CD011224-sec-0136" title="">Characteristics of included studies</a>. Assessment of the risk of bias included evaluation of the following components for each included trial, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011224-bbs2-0041" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We planned to resolve any disagreements by discussion or by involving a third review author. </p> <section id="CD011224-sec-0055"> <h5 class="title">1. Random sequence generation (checking for possible selection bias)</h5> <p> <ul id="CD011224-list-0006"> <li> <p>For each included study, we described the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups. </p> </li> <li> <p>We assessed the methods as low risk of bias (e.g. referring to a random number table or computer random number generator); high risk of bias (e.g. sequence generated by date of birth or admission); or unclear risk of bias. </p> </li> <li> <p>We only included randomised controlled trials.</p> </li> </ul> </p> </section> <section id="CD011224-sec-0056"> <h5 class="title">2. Allocation concealment (checking for possible selection bias)</h5> <p> <ul id="CD011224-list-0007"> <li> <p>For each included study, we described the method used to conceal allocation to intervention prior to assignment and assessed whether intervention allocation could have been foreseen in advance of or during recruitment or changed after assignment. </p> </li> <li> <p>We assessed the methods as low risk of bias (e.g. telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); high risk of bias (e.g. open random allocation; unsealed or non‐opaque envelopes); or unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD011224-sec-0057"> <h5 class="title">3. Blinding of participants, personnel (checking for possible performance bias), and outcome assessment (checking for possible detection bias) </h5> <p> <ul id="CD011224-list-0008"> <li> <p>For each included study, we described the methods used, if any, to blind study participants, personnel, and outcome assessors from knowledge of which intervention a participant had received. We considered studies to be at low risk of bias if they were blinded or if we judged that the lack of blinding would be unlikely to affect results. We considered studies to be at high risk of bias if they were not blinded or if we judged that the lack of blinding would be likely to affect results. </p> </li> <li> <p>We assessed the methods as low risk of bias (e.g. both participants and outcome assessors were blinded); high risk of bias (e.g. neither were blinded); or unclear risk of bias for participants, personnel, and assessors. </p> </li> </ul> </p> </section> <section id="CD011224-sec-0058"> <h5 class="title">4. Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data) </h5> <p> <ul id="CD011224-list-0009"> <li> <p>For each included study, we described the completeness of data, including attrition and exclusions from the analysis. We assessed risk of bias of incomplete outcome data with the overall level of missing data. We stated whether the study reported attrition and exclusions, the numbers included in the analysis at each stage (compared with the total number of randomised participants), and the reasons for attrition or exclusion where disclosed, as well as whether missing data were balanced across groups. Where studies reported sufficient information or the trial authors could supply it, we included missing data in our analyses </p> </li> <li> <p>We assessed methods as low risk of bias (e.g. no missing outcome data; missing outcome data balanced across groups); high risk of bias (e.g. numbers or reasons for missing data imbalanced across groups; 'as treated' analysis done with substantial departure of intervention received from that assigned at randomisation); or unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD011224-sec-0059"> <h5 class="title">5. Selective reporting (checking for reporting bias)</h5> <p> <ul id="CD011224-list-0010"> <li> <p>For each included study, we described how we investigated the possibility of selective outcome reporting bias and what we found. </p> </li> <li> <p>We assessed the methods as low risk of bias (where it was clear that all of the study's prespecified outcomes and all expected outcomes of interest to the review had been reported); high risk of bias (where not all of the study's prespecified outcomes were reported; one or more reported primary outcomes were not prespecified; outcomes of interest were reported incompletely and so could not be used; study failed to include results of a key outcome that would have been expected to have been reported); or unclear risk of bias. </p> </li> </ul> </p> </section> <section id="CD011224-sec-0060"> <h5 class="title">6. Other bias (checking for bias due to problems not covered by items one to five above) </h5> <p> <ul id="CD011224-list-0011"> <li> <p>For each included study, we described any important concerns we had about other possible sources of bias. </p> </li> <li> <p>We assessed whether each study was free of other problems that could put it at risk of bias, classifying each study as at low, high, or unclear risk of other bias. </p> </li> </ul> </p> </section> <section id="CD011224-sec-0061"> <h5 class="title">7. Overall risk of bias</h5> <p> <ul id="CD011224-list-0012"> <li> <p>We made explicit judgements as to whether studies were at high risk of bias, according to the criteria provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD011224-bbs2-0041" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We assessed the overall risk of bias as low when all domains were classified as low risk; unclear when at least one domain was classified as unclear risk; and high when at least one domain was judged as high risk. With reference to items one to six above, we assessed the likely magnitude and direction of the bias and whether we considered that it was likely to impact on the findings. We planned to explore the impact of the level of bias by undertaking sensitivity analyses (see <a href="#CD011224-sec-0069">Sensitivity analysis</a>). </p> </li> <li> <p>We considered trials that were classified as being at low risk of bias in all of the above domains as trials at low risk of bias. We considered trials to be at unclear risk of bias when at least one of the domains was at unclear risk of bias and none of the domains was at high risk of bias, and trials to be at high risk of bias when at least one of the domains was at high risk of bias. </p> </li> </ul> </p> </section> </section> <section id="CD011224-sec-0062"> <h4 class="title">Measures of treatment effect</h4> <p>For dichotomous data, we planned to calculate and present results as summary risk ratios (RR) with 95% confidence intervals (CI). </p> <p>For continuous data, we calculated mean differences (MD) except where continuous outcomes were reported in different units, in which case we calculated a standardised mean difference (SMD). Where studies measured continuous outcomes with different scales and provided commonly used measures of effect, such as standard deviation or standard error, we calculated SMDs with 95% CIs from individual studies. </p> </section> <section id="CD011224-sec-0063"> <h4 class="title">Unit of analysis issues</h4> <p>We included both individual‐ and cluster‐randomised controlled trials. In the event that we included trials with multiple arms, we included the comparisons considered relevant to the review as two‐arm comparisons, with adjustment to avoid double‐counting where appropriate. We analysed the data of the cluster‐randomised trial using the methods described in Section 16.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> if we found such data at the selection stage. </p> </section> <section id="CD011224-sec-0064"> <h4 class="title">Dealing with missing data</h4> <p>For included studies, we noted levels of attrition. We planned to explore the impact of including studies with high levels of missing data on the overall assessment of treatment effect by undertaking sensitivity analysis. </p> <p>For all outcomes, we carried out analyses on an intention‐to‐treat basis to the greatest degree possible, that is we attempted to include all participants randomised to each group in the analyses, and we analysed all participants in the group to which they were allocated, regardless of whether or not they received the allocated intervention. </p> <p>For dichotomous data, we assumed the missing values to have a poor outcome. For continuous data, we considered imputing the mean change from baseline and corresponding standard deviation or, where applicable, the after‐value scores. </p> <p>We contacted the original authors of all studies to enquire if they had any missing data that they did not report in the trial (<a href="#CD011224-tbl-0003">Table 1</a>). In cases where outcome data were not available, we carried out an available‐case analysis. </p> <div class="table" id="CD011224-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Contact history for data collection</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author contacted</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question posed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reply</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date contact letter was sent</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date reply was received</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0020" title="CraigTJ , CorrealeC , ChinchilliV , LehmanE , MendeC , LongerneckerA , et al. The effects of montelukast on atopic dermatitis (AD): a placebo controlled, double blind study. Journal of Allergy, Asthma and Immunolgy2002;109(Suppl 1):S160. [CENTRAL: CN‐00483619] ">Craig 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Craig TJ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We asked whether the conference abstract had subsequently been published as a full article. Additionally, we requested missing data to complete our extraction form. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The author did not have any data and proposed that we seek the data on the clinical trials website. We could not find any additional data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 July 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 October 2015</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0021" title="MelamedIR , RobinsonL , HeffronM . The benefit of montelukast in atopic dermatitis induced by food allergies. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB93. [EMBASE: 70155473] ">Melamed 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Melamed IR and Heffron MG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We asked whether the conference abstract had subsequently been published as a full article. Additionally, we requested missing data to complete our extraction form. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reply</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 July 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Capella GL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The author could not add anything to the data in the article.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 October 2015</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nettis E</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The author no longer had the original data from the trial.</p> <p>No one in the Danish branch of MSD could provide further information about the trial.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 October 2015; 24 November 2015</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Friedmann P and Berth‐Jones J</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reply</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rahman ML</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invalid email address</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Veien NK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reply</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD011224-sec-0065"> <h4 class="title">Assessment of heterogeneity</h4> <p>We evaluated the clinical implications of treatment effects differing between trials. We assessed statistical heterogeneity using the I² statistic. When the I² statistic for each primary outcome was greater than 80%, we did not undertake meta‐analysis, but applied a narrative approach instead. When the I² statistic for each primary outcome was between 50% and 80%, then significant heterogeneity was present, which we planned to explore by looking for differences in participants and treatment factors. </p> </section> <section id="CD011224-sec-0066"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess reporting bias if more than 10 studies were suitable for inclusion in the meta‐analysis, and draw funnel plots for the primary outcomes using the log of effect measure and standard errors for individual studies. Additionally, for continuous outcomes, we planned to use the original linear regression test proposed by Egger (<a href="./references#CD011224-bbs2-0034" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). We planned to perform a linear regression of the intervention effect estimates on their standard errors, weighting by 1/(variance of the intervention effect estimate). For dichotomous outcomes, we planned to use the modified regression test proposed by Harbord (<a href="./references#CD011224-bbs2-0040" title="HarbordRM , EggerM , SterneJA . A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443‐57. [PUBMED: 16345038] ">Harbord 2006</a>). If asymmetry was detected in any of these tests or was suggested by a visual assessment, we planned to perform exploratory analyses to investigate it. </p> </section> <section id="CD011224-sec-0067"> <h4 class="title">Data synthesis</h4> <p>We carried out statistical analysis using Review Manager 5 software. We used random‐effects meta‐analysis to produce an overall summary. We planned to treat the random‐effects summary as the average range of possible treatment effects, and we discussed the clinical implications of treatment effects differing between trials. </p> </section> <section id="CD011224-sec-0068"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If we identified substantial heterogeneity, we planned to investigate it using subgroup analyses and sensitivity analyses. We planned to consider whether an overall summary was meaningful, and if it was, we would use random‐effects analysis to produce it. </p> <p>We planned to carry out the following subgroup analyses:</p> <p> <ul id="CD011224-list-0013"> <li> <p>age of participants: children (16 years old or under) versus adults; and</p> </li> <li> <p>drug preparation, route of administration, dose, duration, frequency, who delivers it to participants, and whether deliverers need to be trained. </p> </li> </ul> </p> <p>We planned to use the following outcomes in subgroup analysis:</p> <p> <ul id="CD011224-list-0014"> <li> <p>change in disease severity;</p> </li> <li> <p>effect of long‐term control; and</p> </li> <li> <p>adverse events.</p> </li> </ul> </p> <p>We were unable to carry out the planned subgroup analysis to evaluate differences in participants and treatment factors due to insufficient data. </p> </section> <section id="CD011224-sec-0069"> <h4 class="title">Sensitivity analysis</h4> <p>We were unable to perform a sensitivity analysis due to insufficient data. In future updates we may be able to conduct sensitivity analysis to assess the effect of studies at high risk of bias on the results </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011224-sec-0070" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011224-sec-0070"></div> <section id="CD011224-sec-0071"> <h3 class="title">Description of studies</h3> <p>We have included all of the primary and secondary outcomes in <a href="./full#CD011224-tbl-0001">summary of findings Table for the main comparison</a> and <a href="./full#CD011224-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD011224-sec-0072"> <h4 class="title">Results of the search</h4> <p>The searches of the six databases (see <a href="#CD011224-sec-0046">Electronic searches</a>) retrieved 158 records after removal of duplicates. Our searches of the trial registries did not produce any further results. We reviewed the references of the included studies but did not identify any additional suitable studies. Of the 158 records, we excluded 137 after analysing their titles and abstracts. We obtained the full text of the remaining 21 records. We excluded 14 studies that did not meet the inclusion criteria after full‐text screening (see <a href="./references#CD011224-sec-0137" title="">Characteristics of excluded studies</a>). We included five studies in the review (see <a href="./references#CD011224-sec-0136" title="">Characteristics of included studies</a>), and assessed two studies as awaiting classification (see <a href="./references#CD011224-sec-0138" title="">Characteristics of studies awaiting classification</a>). The screening process is further described in the study flow diagram (<a href="#CD011224-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011224-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD011224-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD011224-sec-0073"> <h4 class="title">Included studies</h4> <p>Five studies (involving a total of 202 participants) met the inclusion criteria of this review and are summarised in the <a href="./references#CD011224-sec-0136" title="">Characteristics of included studies</a> tables. </p> <section id="CD011224-sec-0074"> <h5 class="title">Design</h5> <p>Three studies were double‐blind trials (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>); one was single‐blind (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>); and one was an open‐label trial (<a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). All five trials included individually randomised participants. </p> </section> <section id="CD011224-sec-0075"> <h5 class="title">Sample sizes</h5> <p>The sample sizes for the five studies ranged from 20 to 60 participants.</p> </section> <section id="CD011224-sec-0076"> <h5 class="title">Setting</h5> <p>Two studies were two‐centre trials (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), and one study was conducted in a single centre (<a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). The other two studies did not report information about setting. Studies were conducted in Italy (two studies), the United Kingdom, Bangladesh, and Denmark. </p> </section> <section id="CD011224-sec-0077"> <h5 class="title">Participants</h5> <p>Participants of one study included children aged six years and above (<a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). The remaining studies did not include children; the age range in these studies was from 16 to 70 years. One study included only men (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>), with the remaining studies including both genders. Study participants were diagnosed with moderate‐to‐severe eczema in four studies (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), and only moderate eczema in one study (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). With regard to coexisting asthma, one study reported that 15 of 32 participants had allergic asthma (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>). </p> </section> <section id="CD011224-sec-0078"> <h5 class="title">Interventions</h5> <p>All studies used montelukast 10 mg for adults (age 14 years and above) or 5 mg for children (age 6 years to 14 years) in tablet form taken orally as the LTRA intervention; three studies compared this with placebo (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), and two studies compared this with conventional treatment (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). Conventional treatment included oral antihistamine and topical corticosteroid in both <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> and <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>, but <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> also included oral antibiotics (clarithromycin) in the conventional treatment arm. Two of the three studies using a placebo tablet did not allow participants in either arm to use topical corticosteroids. </p> <p>The intervention periods varied: 4 weeks in 2 studies (<a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), 6 weeks in 2 studies (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>), and 8 weeks in 1 study (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> </section> <section id="CD011224-sec-0079"> <h5 class="title">Outcomes</h5> <p>All studies assessed disease severity using validated scores such as SCORAD, EASI, or SASSAD. The outcomes and type of data collected in the included studies are provided in <a href="#CD011224-tbl-0004">Table 2</a>. </p> <div class="table" id="CD011224-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of study design and outcomes provided for included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Observation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scale</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, median, mean, range</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, F value, P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SASSAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, Δmean, ΔSD, 95% CI, P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, mean, SD, P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>modified EASI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, mean, P value</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval; EASI: Eczema Area and Severity Index; SASSAD: Six‐Area, Six‐Sign Atopic Dermatitis; SCORAD: SCORing of Atopic Dermatitis; SD: standard deviation </p> </div> </div> <p>The outcome measures varied: for example, different scoring systems were used, and these were analysed using varied measures of effect, which effectively precluded their quantitative comparison. We sought further details of the five included studies from the study contact authors (see <a href="#CD011224-tbl-0003">Table 1</a>), but unfortunately we were unable to obtain additional data beyond those reported in the published papers either because the author(s) did not reply or because they did not possess additional data. We extracted data from the figure in <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> using WebPlotDigitizer software (<a href="./references#CD011224-bbs2-0069" title="AnkitRohatgi . WebPlotDigitizer. Version 3.12. Austin, Texas, USA, 2017. ">WebPlotDigitizer</a>). We performed analyses using available data from the included studies and estimated values using data from relevant studies where possible. </p> </section> </section> <section id="CD011224-sec-0080"> <h4 class="title">Excluded studies</h4> <p>We excluded 14 studies from our search that did not meet our inclusion criteria (see <a href="./references#CD011224-sec-0137" title="">Characteristics of excluded studies</a>). Three of these were reviews, and we checked their references for reports of any other relevant studies. One was not a comparative study, and one was not a randomised controlled trial. One study included participants with other atopic diseases, and as we were unable to separate out the specific effects of LTRA on eczema, we excluded the study. Seven studies were cross‐over trials, and a further reference was related to one of the cross‐over trials. </p> <section id="CD011224-sec-0081"> <h5 class="title">Studies awaiting classification</h5> <p>Two studies were published as conference abstracts (<a href="./references#CD011224-bbs2-0020" title="CraigTJ , CorrealeC , ChinchilliV , LehmanE , MendeC , LongerneckerA , et al. The effects of montelukast on atopic dermatitis (AD): a placebo controlled, double blind study. Journal of Allergy, Asthma and Immunolgy2002;109(Suppl 1):S160. [CENTRAL: CN‐00483619] ">Craig 2002</a>; <a href="./references#CD011224-bbs2-0021" title="MelamedIR , RobinsonL , HeffronM . The benefit of montelukast in atopic dermatitis induced by food allergies. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB93. [EMBASE: 70155473] ">Melamed 2010</a>). We attempted to contact the authors, but to date we have not received any reply (see details in <a href="./references#CD011224-sec-0138" title="">Characteristics of studies awaiting classification</a>). </p> </section> </section> </section> <section id="CD011224-sec-0082"> <h3 class="title">Risk of bias in included studies</h3> <p>The 'Risk of bias' assessment is summarised in <a href="#CD011224-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD011224-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements regarding the level of risk of bias for each type of bias for all included studies." data-id="CD011224-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements regarding the level of risk of bias for each type of bias for all included studies. </p> </div> </div> </div> <p>All but one study, <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>, were published as full papers after the CONSORT statement became well recognised (<a href="./references#CD011224-bbs2-0032" title="SchulzKF , AltmanDG , MoherD . CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ2010;340:c332. [DOI: 10.1136/bmj.c332.] ">CONSORT 2010</a>). However, most studies did not adequately elaborate on their methodology (<a href="./references#CD011224-sec-0136" title="">Characteristics of included studies</a>). </p> <section id="CD011224-sec-0083"> <h4 class="title">Allocation</h4> <section id="CD011224-sec-0084"> <h5 class="title">Random sequence generation</h5> <p>We assessed four studies that inadequately described their method of randomisation as at unclear risk of bias (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>). <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> used computer‐generated randomised sequence; we judged this study to be at low risk of bias for this domain. </p> </section> <section id="CD011224-sec-0085"> <h5 class="title">Allocation concealment</h5> <p>We considered <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>, <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>, <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>, and <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> to be at unclear risk of bias as they did not describe their method of allocation concealment. <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> used containers labelled with sequential participant numbers; we judged this study to be at low risk of bias for allocation concealment. </p> </section> </section> <section id="CD011224-sec-0086"> <h4 class="title">Blinding</h4> <p>Overall, the included studies made efforts to blind participants. We acknowledge that the risk of performance bias is potentially higher in studies comparing LTRA to conventional therapies without placebo, due to the drug delivery mode (e.g. topical versus oral). We have explored how authors attempted to overcome this. <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> tried to minimise outwardly appreciable differences between treatments: the treatment group received oral montelukast, a placebo tablet, and a topical placebo gel, while the control group received an oral antibiotic, oral antihistamine, and topical corticosteroid ointment. However, as this was a single‐blind randomised controlled trial where outcome assessors were not blinded, we therefore considered the study to be at high risk of bias. <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> supplied montelukast and placebo tablets in containers labelled with sequential participant numbers. They blinded treatment allocation to participants and investigators throughout the trial, which we judged to be at low risk of bias for this domain. In the <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> study, placebo tablets were also used, and the code was not broken until all statistical calculations had been performed, but the method of blinding were not described. We therefore judged this study to be at unclear risk of bias. </p> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> was a double‐blind study, but the method of blinding was not described, and therefore the risk of bias was unclear. <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> was an open‐label study, which we judged as at high risk of bias. </p> </section> <section id="CD011224-sec-0087"> <h4 class="title">Incomplete outcome data</h4> <p>In three studies, all participants completed the trial (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). The remaining two studies performed intention‐to‐treat analysis. Two participants in <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> and six in <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> dropped out after randomisation. We therefore judged all studies as at low risk of bias for this domain. </p> </section> <section id="CD011224-sec-0088"> <h4 class="title">Selective reporting</h4> <p>We judged all trials to be at low risk of bias, as the authors reported on all their planned outcomes. </p> </section> <section id="CD011224-sec-0089"> <h4 class="title">Other potential sources of bias</h4> <p>We considered <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> and <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> as at unclear risk of bias because they were funded or supported by the company that sells montelukast. </p> <p>We did not draw funnel plots to assess reporting bias because the review included only five studies. </p> <section id="CD011224-sec-0090"> <h5 class="title">Overall risk of bias</h5> <p>We judged three studies as at unclear risk of bias (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), and two studies as at high risk of bias (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). </p> </section> </section> </section> <section id="CD011224-sec-0091"> <h3 class="title" id="CD011224-sec-0091">Effects of interventions</h3> <p>See: <a href="./full#CD011224-tbl-0001"><b>Summary of findings for the main comparison</b> Montelukast versus placebo for eczema</a>; <a href="./full#CD011224-tbl-0002"><b>Summary of findings 2</b> Montelukast versus conventional treatment for eczema</a> </p> <p>Three studies compared montelukast with placebo (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), and two compared montelukast with conventional treatments (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). We have therefore divided the effects, data and analyses into 'versus placebo' (<a href="./references#CD011224-fig-0005" title="">Analysis 1.1</a>, <a href="./references#CD011224-fig-0006" title="">Analysis 1.2</a>; <a href="./references#CD011224-fig-0007" title="">Analysis 1.3</a>, <a href="./full#CD011224-tbl-0001">summary of findings Table for the main comparison</a>) and 'versus conventional treatment' (<a href="./references#CD011224-fig-0008" title="">Analysis 2.1</a>, <a href="./references#CD011224-fig-0010" title="">Analysis 2.3</a>, <a href="./full#CD011224-tbl-0002">summary of findings Table 2</a>) for each outcome, where available. </p> <section id="CD011224-sec-0092"> <h4 class="title">1. Montelukast versus placebo</h4> <section id="CD011224-sec-0093"> <h5 class="title">i) Primary outcome 1: change in disease severity in the short term and long term</h5> <p>All three studies for the comparison montelukast versus placebo assessed this outcome, for 4 weeks in <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>, 6 weeks in <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>, and 8 weeks in <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>. </p> <p><a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> reported using the modified EASI (Eczema Area and Severity Index) score, which they calculated as the sum of the pruritus scores (0 to 3) and the EASI score. The modified EASI decreased from 8.9 to 6.8 in the montelukast group (n = 25) and from 9.5 to 7.6 in the placebo group (n = 28) (no standard deviations (SDs) provided). The difference between the groups was not significant (P = 0.46, confidence interval not stated) (<a href="./references#CD011224-fig-0005" title="">Analysis 1.1</a>). </p> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> showed a 20% reduction of SCORAD (SCORing of Atopic Dermatitis) scores after six weeks of treatment with montelukast (n = 10), which was a significant decrease compared with placebo (n = 10) (P = 0.021, confidence interval not stated). No raw data were provided (<a href="./references#CD011224-fig-0005" title="">Analysis 1.1</a>). We extracted data from the figure provided in the text using WebPlotDigitizer software (<a href="./references#CD011224-bbs2-0069" title="AnkitRohatgi . WebPlotDigitizer. Version 3.12. Austin, Texas, USA, 2017. ">WebPlotDigitizer</a>), which showed that mean scores changed from 56.07 to 45.81 in the montelukast group and 60.85 to 60.17 in the placebo group after six weeks. </p> <p><a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> evaluated the effect of montelukast on disease severity with SASSAD (Six Area, Six Sign Atopic Dermatitis) and IGA (Investigator's Global Assessment). They found no significant difference between mean SASSAD score changes in the montelukast group (mean ± SD; 1.41 ± 12.2, n = 29) and the placebo group (1.76 ± 12.2, n = 29) (mean difference 0.35, 95% confidence interval (CI) ‐5.93 to 6.63) (<a href="./references#CD011224-fig-0005" title="">Analysis 1.1</a>). </p> <p>Although these studies met our inclusion criteria, they only addressed a restricted version of our review questions in terms of the population, outcomes, and comparators used. We therefore downgraded this evidence due to indirectness as participants all had moderate‐to‐severe eczema with no mild cases or paediatric participants. We also downgraded evidence due to imprecision related to the small sample size: the three relevant studies only included a total of 139 participants. </p> <p>We were able to pool data from the three included studies, involving 131 participants. Participants were treated with either montelukast or placebo (<a href="./references#CD011224-fig-0006" title="">Analysis 1.2</a>, <a href="#CD011224-fig-0003">Figure 3</a>). There was no significant difference in improvement in disease severity for montelukast versus placebo (standardised mean difference 0.29, 95% CI ‐0.23 to 0.81). The I² statistic was 51%, which corresponds to a moderate amount of heterogeneity (<a href="#CD011224-fig-0003">Figure 3</a>). Even if we had based our conclusions on data from two studies, <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>, without using the extracted data from the figure (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>), the overall result would not have substantially changed. </p> <div class="figure" id="CD011224-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.2 Improvement in disease severity." data-id="CD011224-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.2 Improvement in disease severity. </p> </div> </div> </div> </section> <section id="CD011224-sec-0094"> <h5 class="title">ii) Primary outcome 2: effect of long‐term control</h5> <p>We defined three months or more as long term. We found no data evaluating this outcome, as the longest included study was of only eight weeks' duration. </p> </section> <section id="CD011224-sec-0095"> <h5 class="title">iii) Primary outcome 3: adverse events</h5> <p>All three studies reported on this outcome (total of 131 followed participants). We judged the quality of evidence for the outcome adverse events as low, downgrading due to imprecision (small sample size and low event rate) and indirectness because only participants with moderate‐to‐severe eczema were included. Additionally, these were treatment studies, and as such not specifically designed to detect this outcome. </p> <p><a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> reported one serious adverse event of septicaemia and one dizzy spell in 29 participants in the montelukast group, both of which resulted in withdrawal from the study (<a href="./references#CD011224-fig-0007" title="">Analysis 1.3</a>). Although the authors did not comment on whether these effects were thought to be related to the treatment, it seems unlikely that septicaemia was treatment‐related. The authors reported that one participant withdrew due to worsening of eczema in the placebo group. Other adverse events of a fairly mild nature like respiratory tract infections, headache, flares of eczema, and mild gastrointestinal disturbances were observed and according to the authors were "fairly evenly distributed between montelukast and placebo groups". </p> <p>No adverse effects were observed in the 35 participants who received montelukast and the 38 who received placebo in the other two studies (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>). <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> reported a dropout rate of six participants: four in the montelukast group and two in the placebo group. This was due to aggravation of eczema or loss to follow‐up. The authors reported that there was no significant difference between groups in terms of dropout rate (Chi² test for contingency tables, P = 0.62). All participants in the <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> study completed the study. </p> </section> <section id="CD011224-sec-0096"> <h5 class="title">iv) Secondary outcome 1: requirement for any topical or systemic corticosteroids</h5> <p>None of the three studies permitted use of systemic corticosteroids during their trials.</p> <p>Among these studies where topical corticosteroids were not part of the control arm (i.e. where montelukast was compared to placebo), <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> only permitted the use of topical corticosteroids as needed. <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> evaluated the frequency of topical corticosteroid use with a 5‐point scale ("twice daily", "once daily", "alternative days", "occasionally", and "none"), but did not evaluate the amount of steroid used. The frequency of topical corticosteroid usage did not reveal any steroid‐sparing effect (n = 58) (<a href="#CD011224-tbl-0005">Table 3</a>). </p> <div class="table" id="CD011224-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Topical corticosteroid usage in Friedmann 2007</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐2 weeks</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 week</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 weeks</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 weeks</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Montelukast</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alternative day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occasional</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alternative day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occasional</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>The number of participants using topical corticosteroid according to frequency of use at each assessment point of the study. The data were extracted from Figure 2 of the publication, using WebPlotDigitizer software (<a href="./references#CD011224-bbs2-0069" title="AnkitRohatgi . WebPlotDigitizer. Version 3.12. Austin, Texas, USA, 2017. ">WebPlotDigitizer</a>). </p> </div> </div> <p>The other two studies (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> and <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> involving 79 randomised participants) did not permit the use of topical corticosteroids; therefore, neither study was designed to detect steroid‐sparing capacity. </p> <p>We judged the quality of evidence as low, downgrading due to imprecision and indirectness because the outcome was assessed in only one study (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>), which included only 58 evaluable participants who were all adults with moderate‐to‐severe eczema. </p> </section> <section id="CD011224-sec-0097"> <h5 class="title">v) Secondary outcome 2: reduction of pruritus and undesirable skin conditions</h5> <p>Only one study involving 58 participants evaluated pruritus score separately to disease severity (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). The other studies used SCORAD or EASI, which included pruritus scores as one of their outcomes; however, no other study reported a pruritus score independently in their results. </p> <p>In <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>, mean pruritus score at baseline (using a visual analogue scale, range 0 to 10) was 5.8 in the montelukast group (n = 29) and 5.7 in the placebo group (n = 29). The response to treatment was reported as mean improvement in pruritis score, and an improvement of 0.1 was seen in the treatment group and 0.8 in the placebo group. The mean difference was 0.7 (placebo superior to montelukast) on the visual analogue scale. The authors assessed this difference as non‐significant (but provided no P value or SDs). </p> <p><a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> included a modified EASI, which was calculated by adding the traditional EASI score to a pruritis score, measured using a 10‐centimetre 0‐to‐3 visual analogue scale. The primary endpoint was the modified EASI, and the secondary endpoint was the "pruritis score during the trial as a percentage of the baseline value". However, the authors did not provide data from the pruritis score independent of the EASI; therefore, we could not pool these data with those of <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>. </p> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> reported a combined score of daytime pruritis and sleep loss, which was not statistically significant between the two treatments (F‐test = 0.08, P = 0.92), nor was it significant for either group before and after treatment (F‐test = 1.95, P = 0.18). The authors describe recording these "subjective criteria" separate to the SCORAD but do not elucidate on the scoring system. As no actual data (other than graphical representation), mean values, or SDs were provided, we could not further analyse this finding. </p> <p>We judged the quality of this evidence as low, downgrading due to imprecision and indirectness because <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> included only 58 evaluable participants, who were all adults with moderate‐to‐severe eczema. </p> </section> <section id="CD011224-sec-0098"> <h5 class="title">vi) Secondary outcome 3: improvement in quality of life</h5> <p>No studies specifically used this outcome measure.</p> <p>A global assessment scale provided by participants provides some information related to quality of life. One study (involving 58 evaluable participants) reported a participant‐assessed measure of treatment success (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>), which was defined as "better" or "markedly improved" on a seven‐point scale. Out of 29 participants in the montelukast group, six reported success; in the placebo group 10 out of 29 participants reported success. There was no significant difference between groups. Mean sleep disturbance scores are also relevant to this outcome: the mean improvement using a visual analogue scale (range 0 to 10) was 1.0 in the treatment group and 1.6 in the placebo group. Again, there was no significant difference between groups. </p> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> reported a combined score of daytime pruritis and sleep loss, but the difference between the two treatments was not statistically significant (F‐test = 0.08, P = 0.92), nor was it significant for either group before and after treatment (F‐test = 1.95, P = 0.18). The authors describe recording these "subjective criteria" separate to the SCORAD but do not elucidate on the scoring system. As no actual data (other than graphical representation), mean values, or SDs were provided, we could not further analyse this finding. </p> </section> <section id="CD011224-sec-0099"> <h5 class="title">vii) Secondary outcome 4: need for emollient use</h5> <p>Liberal emollient use was permitted in both treatment arms in all three studies (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>; <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>, involving 139 randomised participants). None of the studies evaluated the amount or frequency of emollient use. </p> </section> </section> <section id="CD011224-sec-0100"> <h4 class="title">2. Montelukast versus conventional treatment</h4> <section id="CD011224-sec-0101"> <h5 class="title">i) Primary outcome 1: change in disease severity in the short term and long term</h5> <p>Two of the five included studies used this comparison (involving 63 participants). Treatment with montelukast was compared with conventional treatment for four weeks in the <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> study and six weeks in the <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> study (<a href="./references#CD011224-fig-0008" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> showed that the SCORAD score (mean ± SD) decreased for the montelukast group from 52.70 ± 15.95 to 37.41 ± 6.04 at 4 weeks (P = 0.003), but the score only changed from 53.31 ± 15.17 to 48.58 ± 14.37 (P = 0.088) in the conventional treatment group. The mean difference in improvement in disease severity between groups was 10.57 (95% CI 4.58 to 16.56, P &lt; 0.001, n = 31), in favour of the montelukast group (<a href="./references#CD011224-fig-0009" title="">Analysis 2.2</a>, <a href="#CD011224-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD011224-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Montelukast versus conventional treatment, outcome: 2.2 Improvement in disease severity." data-id="CD011224-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Montelukast versus conventional treatment, outcome: 2.2 Improvement in disease severity. </p> </div> </div> </div> <p><a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> reported a significant improvement of disease severity measured using SCORAD (i.e. a decrease in score) in both the montelukast group (the mean reduced from 49.1 at baseline to 23.9 after 6 weeks) and the conventional treatment group (from 48.2 at baseline to 24.3 at 6 weeks). However, there was no significant difference in medians of SCORAD variations between the montelukast and conventional treatment groups (Mann‐Whitney, P &lt; 0.05). No standard deviation was provided; therefore, we were unable to pool the data from this study with that of <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> without having to make serious assumptions about the exact P value and true standard deviation. </p> <p>We judged the quality of evidence for this outcome as very low, downgrading due to risk of bias, indirectness, and imprecision because outcome assessors were not blinded, and the sample size of each study was small. In addition, participants in these studies only had moderate‐to‐severe eczema; mild cases were not included. </p> </section> <section id="CD011224-sec-0102"> <h5 class="title">ii) Primary outcome 2: effect of long‐term control</h5> <p>We defined three months or more as long term. We found no data evaluating this outcome, as the longest included study was of only six weeks' duration. </p> </section> <section id="CD011224-sec-0103"> <h5 class="title">iii) Primary outcome 3: adverse events</h5> <p>Both studies reported on this outcome. We judged the quality of evidence on adverse events as low, downgrading due to imprecision and indirectness because only 63 participants were evaluated, and only participants with moderate‐to‐severe eczema were included. Additionally, these were treatment studies, and as such not specifically designed to detect this outcome. </p> <p>Neither of the studies reported any adverse effects in the montelukast group (32 participants) (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>) (<a href="./references#CD011224-fig-0010" title="">Analysis 2.3</a>). <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> commented that no side effects were reported by participants or observed by the authors in the montelukast or control group. <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> only commented about the montelukast group, reporting that montelukast was "excellently tolerated". </p> </section> <section id="CD011224-sec-0104"> <h5 class="title">iv) Secondary outcome 1: requirement for any topical or systemic corticosteroids</h5> <p>Neither study permitted use of systemic corticosteroids during their trials.</p> <p>Both studies compared montelukast with conventional treatments that included topical corticosteroids (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> and <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>, a total of 63 out of 202 participants). These studies were therefore not designed to detect steroid‐sparing capacity. </p> </section> <section id="CD011224-sec-0105"> <h5 class="title">v) Secondary outcome 2: reduction of pruritus and undesirable skin conditions</h5> <p>No studies evaluated the effect of montelukast on reduction of pruritus or on undesirable skin conditions compared with conventional treatment. </p> <p>Although they reported no specific data, <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> did mention that "according to patients' impressions, pruritis was the most influenced SCORAD item by both montelukast and conventional groups, immediately followed by sleep loss and inflammatory signs". This study found no significant difference in SCORAD scores before and after treatment between treatment groups, but as the authors did not provide further data on this specific measure, we were unable to use this information in our analyses. </p> <p>Interestingly, <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> also reported that "according to patients' impressions, pruritis was the most influenced SCORAD item... followed by sleep loss and inflammatory signs", but did not provide any specific data to support this or enable further analysis. The authors of this study reported that the overall SCORAD was significantly improved after four weeks in the montelukast group but not in the group received conventional treatment, and there was a significant difference between montelukast and control groups at four weeks (P = 0.001). </p> </section> <section id="CD011224-sec-0106"> <h5 class="title">vi) Secondary outcome 3: improvement in quality of life</h5> <p>No studies specifically used this outcome measure.</p> <p>However, sleep disturbance is one of the most important parameters when assessing quality of life. Although they reported no specific data, <a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> did mention that "according to patients' impressions, pruritis was the most influenced SCORAD item by both M (montelukast) and C (conventional) groups, immediately followed by sleep loss...". This study found no significant difference in SCORAD scores before and after treatment between treatment groups, but did not provide further data on this specific measure. </p> <p><a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> also reported that "according to patients' impression pruritis was the most influenced SCORAD item followed by sleep loss and inflammatory signs", but did not provide any specific data to support this or enable further analysis. The authors of this study reported that the overall SCORAD was significantly improved after four weeks in the montelukast group but not in the group received conventional treatment, and there was a significant difference between montelukast and control groups at four weeks (P = 0.001). </p> </section> <section id="CD011224-sec-0107"> <h5 class="title">vii) Secondary outcome 4: need for emollient use</h5> <p>In one study, emollient use was included in the conventional treatment arm, which was compared with montelukast (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>). <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> did not provide details of emollient use. Neither study evaluated the amount or frequency of emollient use. </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011224-sec-0108" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011224-sec-0108">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011224-sec-0179">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011224-sec-0108"></div> <section id="CD011224-sec-0109"> <h3 class="title" id="CD011224-sec-0109">Summary of main results</h3> <p>Based on evidence from five studies involving a total of 202 participants contributing data to the objectives of our review, we found that the impact of LTRAs on eczema is uncertain. These findings are demonstrated quantitatively in our 'Summary of findings' tables (<a href="./full#CD011224-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011224-tbl-0002">summary of findings Table 2</a>). </p> <p>All trials were short term in duration (four to eight weeks) and assessed moderate‐to‐severe eczema, so the effects of LTRA in milder cases of eczema remain uncertain. Reported outcomes were measured at the end of treatment. None of our included studies evaluated the need for emollient use or improvement in quality of life. All five studies used montelukast; therefore, we could draw no conclusions about other LTRAs. Two of the five included studies had funding links to the drug manufacturer. We excluded a number of studies looking at the effect of montelukast because they had a cross‐over design, which was an exclusion criterion of this review. </p> <p>Alternative oral agents used in eczema have significant safety profiles, and topical agents are often poorly tolerated resulting in poor compliance, so a review of the adverse effects of montelukast was particularly relevant. As per our objectives, we reviewed the number of reported adverse effects in the five included studies. All studies explicitly reported on adverse effects (giving a total of 101 participants taking montelukast). </p> <section id="CD011224-sec-0110"> <h4 class="title">Montelukast versus placebo</h4> <p>(See <a href="./full#CD011224-tbl-0001">summary of findings Table for the main comparison</a>.) </p> <p>With regard to change in disease severity, we found no evidence of a difference between montelukast (10 mg) and placebo in terms of mean improvement (3 studies, n = 131), reduction of pruritus (1 study, n = 58), or topical corticosteroid use (1 study, n = 58). We assessed the quality of this evidence as low. </p> <p>In all three studies (131 participants) in this comparison, there were only two reported adverse effects (septicaemia and dizziness) that resulted in withdrawal (both occurred in the same study). The most serious of these adverse effects, a "brief septicaemic episode", is not a recognised side effect of montelukast, and it seems unlikely that it would have been related to the treatment. Mild adverse effects such as respiratory tract infections, headache, and mild gastrointestinal disturbances were reported fairly evenly in both intervention groups. We therefore found no evidence that montelukast treatment results in more adverse events than placebo. However, restrictions such as number of participants and characteristics of participants resulted in the downgrading of the evidence on adverse effects to low quality, meaning we have only limited confidence in this conclusion. </p> </section> <section id="CD011224-sec-0111"> <h4 class="title">Montelukast versus conventional treatment</h4> <p>(See <a href="./full#CD011224-tbl-0002">summary of findings Table 2</a>.) </p> <p>Both of the studies in this comparison reported that none of the participants experienced adverse effects; these studies did not report on reduction of pruritus or topical corticosteroid use. </p> <p>Although montelukast improved disease severity compared with conventional treatment in one study (n = 31), another study showed no clear difference (n = 32); however, we are uncertain about these results because the quality of the evidence was very low. </p> <p>Overall, there was a lack of studies that sought to answer our review questions, and therefore the participant numbers included in this review were relatively low. There were no studies that explored the longer‐term impact of montelukast, and therefore we were unable to draw any conclusions about the role of montelukast in maintenance therapy for eczema. </p> <p>We hoped to be able to perform subgroup analysis of effects of LTRA in children versus adults, but only one out of the five included studies recruited both adults and children as participants (<a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). Consequently, it is difficult to comment on the role of LTRA in the paediatric population. More evidence on the paediatric population would be helpful because this group is likely to benefit most from steroid‐sparing agents, as children have more eczema and may potentially be on steroids longer and thus have more lifetime side effects from steroids. </p> <p>Overall, insufficient studies met our inclusion criteria to enable us to provide a sound meta‐analysis or robust conclusions. The included studies mostly failed to adequately report on methods of allocation and blinding, thus preventing appropriate bias categorisation. As with other research on treatments in eczema, the study period was unanimously short term, which prevents us from commenting on the role of LTRA in long‐term maintenance (a facet of eczema that is very important to many eczema sufferers). </p> </section> </section> <section id="CD011224-sec-0112"> <h3 class="title" id="CD011224-sec-0112">Overall completeness and applicability of evidence</h3> <p>Overall, the objectives of this review were not fully addressed, hence external validity is weak. There was an overall lack of evidence that met our inclusion criteria; we needed more randomised controlled trials to evaluate whether LTRAs are as good as conventional therapies, or at least significantly better than placebo. However, all studies did report specifically on the adverse effects of LTRA. </p> <p>Studies used varied outcome measures and did not always provide commonly used measures of effect, such as standard deviation or standard error, and therefore we were unable to combine results to the degree we would have liked, in order to provide a risk ratio. We contacted authors of some included and excluded studies to request more information, but unfortunately did not receive positive replies to help our cause. There was also a lack of explicit evidence to enable a thorough analysis of our secondary outcomes (corticosteroid‐sparing ability, quality of life, and emollient use). Furthermore, most study participants were adults, and one study only included men aged 18 to 28, making the results potentially less generalisable to all individuals with eczema. </p> <p>We did not find any studies that evaluated the effect on long‐term control. The treatment periods for all five studies were relatively short (four to eight weeks) given that eczema is a chronic condition. Studies with a longer treatment and follow‐up duration were not identified in this review. </p> <p>The pathophysiology of eczema is complex: genetic and environmental factors contribute to different extents in different populations. With this in mind, LTRA may in fact be beneficial only in a subgroup of eczema sufferers, where their underlying pathogenic process is different to the majority. Equally, LTRA may be completely ineffective in eczema overall. The subgroup of those with eczema and asthma would be worth evaluation, because this phenotype might theoretically have a better response to montelukast than those with eczema only. Only one of our included studies included participants with both eczema and asthma (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>), but we were unable to conduct any sensitivity analyses on this subgroup. </p> <p>We had to exclude some studies as they included participants with "atopic conditions" rather than specifying which results related to those with eczema versus asthma. We excluded cross‐over trials because we could not exclude hangover effect of LTRAs after the washout period; given the natural variability of eczema severity, we felt this study design was less reliable than randomised controlled trials. </p> <p>There are also concerns about the choice of comparator in the studies using "conventional treatment" (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). In one study oral antibiotics were used (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>), which is not standard treatment of eczema unless acutely infected. The other study used a very mild topical corticosteroid, which may have been inadequate for the severity of eczema in the group (<a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). </p> <p>In the absence of further research, the findings of this review are unlikely to change current clinical practice; current international guidelines do not advocate LTRA at present for eczema due to insufficient evidence (see <a href="#CD011224-sec-0115">Agreements and disagreements with other studies or reviews</a>). </p> </section> <section id="CD011224-sec-0113"> <h3 class="title" id="CD011224-sec-0113">Quality of the evidence</h3> <p>We included only five studies with a total of 202 participants in this review, and most studies lacked sufficiently detailed information to enable a meta‐analysis. Hence, the body of evidence does not permit a robust conclusion regarding the effect of LTRAs in eczema and their adverse effects in this patient group. </p> <p>Serious limitations were that all studies only included people with moderate‐to‐severe eczema and that each outcome was evaluated with a small sample size, if at all. Hence, we downgraded all outcomes for imprecision and indirectness, and considered the quality of evidence as low for all outcomes in the comparison of montelukast versus placebo. For the comparison of montelukast versus conventional treatment, we also considered the evidence for adverse effects as low quality for the reasons given above, but graded our primary outcome of change in disease severity as very low quality because the outcome assessors were not blinded, causing us to further downgrade for study limitations (see <a href="./full#CD011224-tbl-0001">summary of findings Table for the main comparison</a>; <a href="./full#CD011224-tbl-0002">summary of findings Table 2</a>). </p> <p>Even though we only downgraded one outcome for study limitations, there were further methodological uncertainties with regard to allocation and blinding. There was uncertainty in how participants were allocated to their groups in four of the five studies, rendering comments on overall bias challenging. Only three studies were double‐blind; hence, we agree with the comment in <a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> stating that "Given the natural variability of eczema over time and the subjective nature of the condition, uncontrolled, unblinded studies should be interpreted with caution", and think this is very relevant to our review. In addition, some study reports had missing numerical data, which made the pooling of studies challenging. </p> </section> <section id="CD011224-sec-0114"> <h3 class="title" id="CD011224-sec-0114">Potential biases in the review process</h3> <p>We searched and re‐searched the literature several times to avoid missing studies. Two review authors filtered studies to avoid any bias. We asked a third party to translate any studies published in languages not spoken by the review authors. We were unable to include two studies published as conference abstracts due to lack of information on methods, despite contacting the authors to request more information. This was a restriction outside of our control. We attempted to conduct a comprehensive search for studies, but the fact that two studies, <a href="./references#CD011224-bbs2-0020" title="CraigTJ , CorrealeC , ChinchilliV , LehmanE , MendeC , LongerneckerA , et al. The effects of montelukast on atopic dermatitis (AD): a placebo controlled, double blind study. Journal of Allergy, Asthma and Immunolgy2002;109(Suppl 1):S160. [CENTRAL: CN‐00483619] ">Craig 2002</a>; <a href="./references#CD011224-bbs2-0021" title="MelamedIR , RobinsonL , HeffronM . The benefit of montelukast in atopic dermatitis induced by food allergies. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB93. [EMBASE: 70155473] ">Melamed 2010</a>, have not yet been incorporated is a potential source of bias. We attempted to contact the authors of all included studies for further information, but none was provided (<a href="#CD011224-tbl-0003">Table 1</a>). The way we corresponded with study authors was limited to email in all cases. As we were unable to perform a full statistical meta‐analysis (due to a lack of comparable outcome measures and varied participant groups), any conclusions drawn are based on the review authors' interpretation of the studies. However, given that results were conflicting and the evidence of low quality, there were no robust conclusions, so this limitation of the review process is unlikely to have introduced significant bias. We also had to rely on WebPlotDigitizer software to extract data that had not been provided in a usable format in one study (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0069" title="AnkitRohatgi . WebPlotDigitizer. Version 3.12. Austin, Texas, USA, 2017. ">WebPlotDigitizer</a>). </p> </section> <section id="CD011224-sec-0115"> <h3 class="title" id="CD011224-sec-0115">Agreements and disagreements with other studies or reviews</h3> <p>Our included studies appear to fit with other recent systematic reviews and guidelines in the literature. In the UK, LTRAs are not part of the stepped approach to management of eczema in children up to the age of 12 (<a href="./references#CD011224-bbs2-0050" title="National Institute for Health and Clinical Excellence. Atopic eczema in children. Management of atopic eczema in children from birth up to the age of 12 years. NICE clinical guideline 572007. [www.nice.org.uk/nicemedia/pdf/cg057niceguideline.pdf] ">NICE 2007</a>). The European Dermatology Forum, whose systematic review informed the guidelines for treatment of eczema (<a href="./references#CD011224-bbs2-0055" title="RingJ , AlomarA , BieberT , DeleuranM , Fink‐WagnerA , GelmettiC , et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. Journal of the European Academy of Dermatology and Venereology2012;26(8):1045‐60. [PUBMED: 22805051] ">Ring 2012</a>), stated that "at the moment there is not enough RCT [randomised controlled trial] evidence to support the safe use of leukotriene receptor antagonists in the treatment of AE [atopic eczema] itch". Similarly, recent American systematic review guidelines on eczema management state that "leukotriene inhibitors have limited data. Thus, it is difficult to determine the relative efficacy of available options" (<a href="./references#CD011224-bbs2-0061" title="SidburyR , DavisDM , CohenDE , CordoroKM , BergerTG , BergmanJN , et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology2014;71(2):327‐49. [PUBMED: 24813298] ">Sidbury 2014</a>). In Japan, systematic review guidelines include no data for LTRA (<a href="./references#CD011224-bbs2-0046" title="KatayamaI , KohnoY , AkiyamaK , AiharaM , KondoN , SaekiH , et al. Japanese Guideline for Atopic Dermatitis 2014. Allergology International2014;63(3):377‐98. [PUBMED: 25178178] ">Katayama 2014</a>). Another systematic review found, like our review, that the "results of these trials are inconsistent" (<a href="./references#CD011224-bbs2-0058" title="RoekevischE , SpulsPI , KuesterD , LimpensJ , SchmittJ . Efficacy and safety of systemic treatments for moderate‐to‐severe atopic dermatitis: a systematic review. Journal of Allergy &amp; Clinical Immunology2014;133(2):429‐38. [PUBMED: 24269258] ">Roekevish 2014</a>). </p> <p>Amongst recent publications not based on systematic review methodology, the conclusions have been more positive in favour of LTRA. For example, a journal club search based on a paediatric subset concluded that "montelukast can significantly reduce the severity of atopic dermatitis, albeit with less effect on disease extent" (<a href="./references#CD011224-bbs2-0011" title="HolmeH , WinckworthLC . Montelukast can reduce the severity and extent of atopic dermatitis. Journal of Paediatrics and Child Health2013;49(5):412‐5. [PUBMED: 23647765] ">Holme 2013</a>). The authors commented that there may be "subgroups within the population that respond better to montelukast treatment", and therefore a "month long trial is reasonable". More trial data covering the paediatric population are needed in order to endorse these claims. </p> <p>Potential adverse effects of LTRA detailed by the manufacturers and in other extensive literature on asthma include gastrointestinal disturbances, headache, hypersensitivity reactions, drowsiness, and neuropsychiatric effects including the potential for mood changes and suicidal ideation. In line with other literature, this review found that the rate of adverse effects reported with montelukast may be low (2 adverse incidents from 101 participants, which resulted in study withdrawal). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011224-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/urn:x-wiley:14651858:media:CD011224:CD011224-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_t/tCD011224-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD011224-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011224-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/urn:x-wiley:14651858:media:CD011224:CD011224-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_t/tCD011224-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements regarding the level of risk of bias for each type of bias for all included studies." data-id="CD011224-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements regarding the level of risk of bias for each type of bias for all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011224-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/urn:x-wiley:14651858:media:CD011224:CD011224-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_t/tCD011224-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.2 Improvement in disease severity." data-id="CD011224-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Montelukast versus placebo, outcome: 1.2 Improvement in disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011224-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/urn:x-wiley:14651858:media:CD011224:CD011224-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_t/tCD011224-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Montelukast versus conventional treatment, outcome: 2.2 Improvement in disease severity." data-id="CD011224-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Montelukast versus conventional treatment, outcome: 2.2 Improvement in disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011224-fig-0005"> <p> <div class="table" id="CD011224-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Friedmann 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The montelukast effect on disease severity with SASSAD and IGA. They found no significant difference between<br/> mean score changes in the montelukast group (mean ± SD; 1.41 ± 12.2) and the placebo group (1.76 ± 12.2) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nettis 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A 20% reduction of SCORAD scores after 6 weeks of treatment with montelukast, and this was a significant<br/> decrease compared with placebo (P = 0.021) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veien 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The modified EASI score, the sum of EASI score and the pruritus scores (0 ‐ 3), decreased from 8.9 to 6.8 in<br/> the montelukast group and from 9.5 to 7.6 in the placebo group. The difference between the groups was not<br/> significant (P = 0.46) </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Montelukast versus placebo, Outcome 1 Improvement in disease severity (narrative table). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-fig-0005">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011224-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/urn:x-wiley:14651858:media:CD011224:CD011224-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_t/tCD011224-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Montelukast versus placebo, Outcome 2 Improvement in disease severity." data-id="CD011224-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Montelukast versus placebo, Outcome 2 Improvement in disease severity.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011224-fig-0007"> <p> <div class="table" id="CD011224-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Friedmann 2007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 serious adverse event of septicaemia and 1 dizzy spell in 29 participants of the montelukast group. 1 worsening of eczema causing withdrawal of the trial in the placebo group. Other adverse events of a fairly mild nature like respiratory tract infections, headache, flares of eczema and mild gastrointestinal disturbances were observed and they were "fairly evenly distributed between montelukast and placebo groups" according to the authors. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nettis 2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse effects were observed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veien 2005</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse effects were observed.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Montelukast versus placebo, Outcome 3 Adverse effects (narrative table).</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-fig-0007">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011224-fig-0008"> <p> <div class="table" id="CD011224-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capella 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>A significant improvement of SCORAD score both in the montelukast group (mean: from 49.1 to 23.9) and the conventional treatment group (from 48.2 to 24.3). There was no significant difference between the groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rahman 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Montelukast significantly improved the SCORAD score compared with conventional treatment (P = 0.001). In the montelukast group, the score (mean ± SD) decreased from 52.70 ± 15.95 to 37.41 ± 6.04 (P = 0.003); otherwise the score changed from 53.31 ± 15.17 to 48.58 ± 14.37 (P=0.088) in the conventional group. </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Montelukast versus conventional treatment, Outcome 1 Improvement in disease severity (narrative table). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-fig-0008">Navigate to figure in review</a></div> </div> <div class="figure" id="CD011224-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/urn:x-wiley:14651858:media:CD011224:CD011224-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_t/tCD011224-CMP-002-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Montelukast versus conventional treatment, Outcome 2 Improvement in disease severity." data-id="CD011224-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Montelukast versus conventional treatment, Outcome 2 Improvement in disease severity. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/media/CDSR/CD011224/image_n/nCD011224-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011224-fig-0010"> <p> <div class="table" id="CD011224-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Capella 2001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse effects were observed.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rahman 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse effects were observed.</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Montelukast versus conventional treatment, Outcome 3 Adverse effects (narrative table). </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-fig-0010">Navigate to figure in review</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011224-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Montelukast versus placebo for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Montelukast compared with placebo for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> eczema<br/> <b>Setting:</b> 2 studies were conducted in 2 centres each; setting of remaining study is unknown<br/> <b>Intervention:</b> montelukast<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Montelukast</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change (improvement) in disease severity</b> </p> <p>(4 to 8 weeks)</p> <p>SMD (modified EASI score and SASSAD)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement score ranged across placebo group from 0.68 to 1.9.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in the intervention group was 0.29 higher (0.23 lower to 0.81 higher). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect of long‐term control</b> (&gt; 3 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured, as longest follow‐up was only 8 weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>(4 to 8 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131</p> <p>(3 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 adverse events were reported (1 episode of septicaemia and 1 dizzy spell in the montelukast group) out of 29 participants (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> <p>No adverse effects were observed in the other 2 studies (<a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a>; <a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a>), but <a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> reported an equivalent dropout rate in both montelukast and placebo groups due to aggravation of eczema or loss to follow‐up. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Requirement for corticosteroid (steroid‐sparing</b> <br/> <b>effect)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The frequency of topical corticosteroids use was not significantly different between montelukast and placebo treatments using a 5‐point scale (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of pruritus</b> </p> <p>(score range 0 to 10; higher score means better improvement)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in improvement of pruritus score from baseline was 0.8 in the placebo group. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean change in improvement of pruritus score from baseline was 0.7 lower in the montelukast group. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The study authors assessed this difference as non‐significant (but no P value or standard deviations provided) (<a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies evaluated quality of life.</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for emollient use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No studies evaluated emollient requirement.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>EASI:</b> Eczema Area and Severity Index; <b>RCT:</b> randomised controlled trial; <b>SASSAD:</b> Six‐Area, Six‐Sign Atopic Dermatitis; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded by two levels, one level due to imprecision because the total number of participants included in all studies was insufficient; and one level due to indirectness because the studies only included adults with moderate‐to‐severe eczema, with no evidence from those with mild eczema or paediatric patients. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Montelukast versus placebo for eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD011224-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Montelukast versus conventional treatment for eczema</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Montelukast compared with conventional treatment for eczema</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> eczema<br/> <b>Setting:</b> 1 study was conducted in a single centre; the setting of the other study is unknown<br/> <b>Intervention:</b> montelukast<br/> <b>Comparison:</b> conventional treatment (topical corticosteroid and oral antihistamine +/‐ oral antibiotics) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No. of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Conventional treatment</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Montelukast</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Change (improvement) in disease severity</b> </p> <p>(4 weeks)</p> <p>SCORAD score</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in severity score was 4.73.</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean improvement in severity score in the intervention group was 10.57 units greater (4.58 greater to 16.56 greater). </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY<br/> LOW <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Another study with 32 participants reported no significant difference in SCORAD between the montelukast (mean improvement = 25.2 points) and conventional treatment (mean improvement = 23.9) (6 weeks follow‐up) groups (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>), but the authors did not provide the statistical values needed to calculate standard deviation, thus we could not pool these data. </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Effect of long‐term control</b> (&gt; 3 months) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not measured, as longest follow‐up was only 6 weeks</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse effects</b> </p> <p>(4 to 6 weeks)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> <p>(2 RCTs)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 studies reported no adverse effects (<a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a>; <a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a>). </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Requirement for corticosteroid (steroid‐sparing</b> <br/> <b>effect)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reduction of pruritus</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Improvement in quality of life</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Need for emollient use</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated in either study</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>SCORAD:</b> SCORing of Atopic Dermatitis </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>We downgraded by three levels: one level due to imprecision because the total number of participants included in the study was insufficient; a second level due to indirectness because the study only included adults with moderate‐to‐severe eczema, with no evidence from those with mild eczema or paediatric patients; and a third level due to risk of bias because the outcome assessors were not blinded.<br/> <sup>2</sup>We downgraded by two levels: one level due to imprecision because the total number of participants included in the studies was insufficient; and one level due to indirectness because the studies only included adults with moderate‐to‐severe eczema, with no evidence from those with mild eczema or paediatric patients. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Montelukast versus conventional treatment for eczema</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011224-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Contact history for data collection</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Author contacted</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Question posed</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reply</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date contact letter was sent</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Date reply was received</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0020" title="CraigTJ , CorrealeC , ChinchilliV , LehmanE , MendeC , LongerneckerA , et al. The effects of montelukast on atopic dermatitis (AD): a placebo controlled, double blind study. Journal of Allergy, Asthma and Immunolgy2002;109(Suppl 1):S160. [CENTRAL: CN‐00483619] ">Craig 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Craig TJ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We asked whether the conference abstract had subsequently been published as a full article. Additionally, we requested missing data to complete our extraction form. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The author did not have any data and proposed that we seek the data on the clinical trials website. We could not find any additional data. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 July 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 October 2015</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0021" title="MelamedIR , RobinsonL , HeffronM . The benefit of montelukast in atopic dermatitis induced by food allergies. Journal of Allergy and Clinical Immunology2010;125(2 Suppl 1):AB93. [EMBASE: 70155473] ">Melamed 2010</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Melamed IR and Heffron MG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We asked whether the conference abstract had subsequently been published as a full article. Additionally, we requested missing data to complete our extraction form. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reply</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 July 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Capella GL</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The author could not add anything to the data in the article.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 October 2015</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nettis E</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The author no longer had the original data from the trial.</p> <p>No one in the Danish branch of MSD could provide further information about the trial.</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 October 2015; 24 November 2015</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Friedmann P and Berth‐Jones J</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reply</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rahman ML</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Invalid email address</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Veien NK</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We requested additional analytical data for each group and full data on the eczema severity scores to provide missing outcome measures for the meta‐analysis. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No reply</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 October 2015</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Contact history for data collection</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011224-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of study design and outcomes provided for included studies</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Comparison</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Observation</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Scale</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0001" title="CapellaGL , FrigerioE , AltomareG . A randomized trial of leukotriene receptor antagonist montelukast in moderate‐to‐severe atopic dermatitis of adults. European Journal of Dermatology2001;11(3):209‐13. [CENTRAL: CN‐00347986; PUBMED: 11358726] ">Capella 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, median, mean, range</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0003" title="NettisE , PannofinoA , FanelliM , FerranniniA , TursiA . Efficacy and tolerability of montelukast as a therapeutic agent for severe atopic dermatitis in adults. Acta dermato‐venereologica2002;82(4):297‐8. [CENTRAL: CN‐00422152; EMBASE: 35015053] ">Nettis 2002</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, F value, P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0002" title="FriedmannPS , PalmerR , TanE , OgboliM , BarclayG , HotchkissK , et al. A double‐blind, placebo‐controlled trial of montelukast in adult atopic eczema. Clinical and Experimental Allergy2007;37(10):1536‐40. [CENTRAL: CN‐00612029; PUBMED: 17850382] ">Friedmann 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SASSAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, Δmean, ΔSD, 95% CI, P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0004" title="RahmanML , ChoudhuryAM , IslamMM . Effectiveness of montelukast in the treatment of atopic dermatitis. Mymensingh Medical Journal2006;15(1):85‐8. [CENTRAL: CN‐00562538; PUBMED: 16467770] ">Rahman 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Conventional treatment</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SCORAD</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, mean, SD, P value</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011224-bbs2-0005" title="VeienNK , Busch‐SorensenM , Stausbol‐GronB . Montelukast treatment of moderate to severe atopic dermatitis in adults: a randomized, double‐blind, placebo‐controlled trial. Journal of the American Academy of Dermatology2005;53(1):147‐9. [CENTRAL: CN‐00551665; PUBMED: 15965438] ">Veien 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Placebo</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>modified EASI</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n, mean, P value</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>CI: confidence interval; EASI: Eczema Area and Severity Index; SASSAD: Six‐Area, Six‐Sign Atopic Dermatitis; SCORAD: SCORing of Atopic Dermatitis; SD: standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary of study design and outcomes provided for included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011224-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Topical corticosteroid usage in Friedmann 2007</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>‐2 weeks</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>0 week</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>4 weeks</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>8 weeks</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Montelukast</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alternative day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occasional</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Twice daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Once daily</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Alternative day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Occasional</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>The number of participants using topical corticosteroid according to frequency of use at each assessment point of the study. The data were extracted from Figure 2 of the publication, using WebPlotDigitizer software (<a href="./references#CD011224-bbs2-0069" title="AnkitRohatgi . WebPlotDigitizer. Version 3.12. Austin, Texas, USA, 2017. ">WebPlotDigitizer</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Topical corticosteroid usage in Friedmann 2007</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/full#CD011224-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011224-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Montelukast versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in disease severity (narrative table) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Improvement in disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [‐0.23, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects (narrative table) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Montelukast versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011224-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Montelukast versus conventional treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Improvement in disease severity (narrative table) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Improvement in disease severity <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.57 [4.58, 16.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse effects (narrative table) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Montelukast versus conventional treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011224.pub2/references#CD011224-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011224.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011224-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011224-note-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011224-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD011224-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD011224-note-0004">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD011224-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011224-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011224\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011224\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011224\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011224\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011224\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=na56WA6j&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011224.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011224.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011224.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011224.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011224.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724330998"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011224.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724331002"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011224.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e60350ddcf409',t:'MTc0MDcyNDMzMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 